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ABSTRACT 
 
 
 Background. Infertility treatment protocols require women to engage in self-
management of their prescribed medication regimens, yet adherence to infertility medication 
schedules have been suboptimal. No prior research has investigated barriers to and 
facilitators of infertility medication adherence (MA) that could assist in the development of 
effective interventions to overcome medication non-adherence (MNA).  
 Purpose. The purpose of this study was to assess barriers to and facilitators of 
infertility MA among women undergoing infertility treatment. This study was approved by 
the University of Missouri-Kansas City Institutional Review Board (IRB) and followed the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines.  
 Setting. The study setting was a reproductive medicine and infertility clinical 
practice serving women who reside in urban, suburban, and rural communities.  
 Methods. Supported by Ajzen and Fishbein’s Reasoned Action Model, a convergent 
mixed methods design was conducted to correlate women’s perceived barriers to and 
facilitators of infertility MA. Women in a convenience sample were interviewed and 
completed questionnaires at study onset followed by one to two subsequent months of 
iv 
electronically monitored medication-taking using the Medication Event Management 
System® (MEMS).  
 Results. The total sample consisted of 30 participants, of which 18 (60%) 
participants used the MEMS® with infertility medication-taking. The overall median 
infertility adherence MA score was 0.98 with a range of .75 to 1.00. The median adherence 
score of women who were considered non-adherent (n=9) was 0.90, and those who were 
considered adherent (n=9) was 1.00. MA scores significantly (r = -.49, p= 0.020) increased 
when the total MA barrier scores decreased. Women with a higher MA total barrier scores 
had significantly (p= 0.019) lower MA scores compared to women with lower total barrier 
scores. Women who were adherent to their infertility medication regimen had a significantly 
(p= 0.009) higher probability to report a positive view on treatment success compared to 
women who were not adherent. Women who lived in urban and rural communities had a 
significantly (p= 0.010) higher probability to report a positive view regarding treatment 
success compared to women who lived in suburban communities. Caucasian and African-
American women had a significantly (p= 0.049) higher probability to report feelings of self-
blame for experiencing infertility compared to Asian, Hispanic, and Native American 
women. Women who had experienced two to three prior failed treatment cycles had a 
significantly (p= 0.047) higher probability to report feelings of emotional distress compared 
to women who had experienced zero to one prior failed cycle. Women with children had a 
significantly (p= 0.015) lower probability to report having a supportive partner compared to 
women who were childless. There were no significant relationships found between the 
reported MA facilitators and infertility MA scores.  
v 
Conclusion. These study findings offer new insight about this unique population that 
could impact the future of clinical practice. This study serves as a framework to foster 
ongoing scientific discovery including new interventional studies aimed at optimizing 
infertility MA.  
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CHAPTER 1 
INTRODUCTION 
 Infertility is a condition that impacts 16% of reproductive aged women in the United 
States, and many women undergo infertility treatment in an attempt to become pregnant 
(Chandra, Copen, & Stephen, 2014; Thoma et al., 2013). Infertility treatment protocols 
require women to engage in self-management of their prescribed medication regimens, yet 
adherence to infertility medication schedules has been suboptimal, with medication non-
adherence (MNA) rates ranging widely from 19% to 74% (Kruse, Eggert-Kruse, 
Rampmaier, Runnebaum, & Weber, 1990, 1991, 1993; Li, He, Yang, Yin, & Xu, 2011; 
McGovern et al., 2008). Infertility treatment regimens are complex, cycle-based (one 
treatment plan per cycle) and can impede women’s daily lives (Boivin et al., 2012; Wu, 
Elliot, Katz, & Smith, 2013). Treatment cycles can incorporate multiple oral and/or 
injectable medications. Medication schedules range from daily to multiple daily dosing that 
is very time sensitive (Smith, Grimm, & Schwegel, 2012). Women with infertility are 
challenged by physical, psychological, emotional, and financial demands that can 
accompany treatment (Brod, Verhaak, Wiebinga, Gerris, & Hoomans, 2009). Still, 
researchers have not established a systematic process to monitor or improve medication 
adherence (MA) supported by a theoretical foundation. Failure to correctly take the 
medication during a treatment cycle decreases the likelihood of the medication having its 
intended effect on reproductive hormones, ovarian follicular development, and pregnancy, 
thus ultimately driving up healthcare costs for repeated treatments (Katz et al., 2011; 
Noorhasan, McCulloh, Cho, & McGovern, 2008). The cost per successful pregnancy and 
birth for all women who undergo cycle-based treatment is over $48,000 (Katz et al., 2011).  
2 
  Adherence can be defined as “the extent to which a person’s behavior—medication 
taking, following a diet, and/or executing lifestyle changes—corresponds with agreed 
recommendations from a health care provider” (Sabaté & World Health Organization, 2003, 
p. 3). Medication adherence is the degree to which individuals take their medications as 
prescribed and consists of three important components that include initiation, 
implementation, and discontinuation (Vrijens et al., 2012). Initiation occurs when the 
individual takes the first prescribed medication dose. Implementation is the extent to which 
the individual’s actual dosing behaviors align with the prescribed dosing regimen (Vrijens et 
al., 2012). Discontinuation designates the time-point for which the next dose to be taken is 
omitted and medication-taking subsides (Vrijens et al., 2012). MNA occurs with late 
initiation, suboptimal implementation, and/or early discontinuation of prescribed medication 
regimens (Vrijens et al., 2012).  
While MA intervention research has identified, compared, and improved health 
outcomes across acute and chronic populations, women undergoing infertility treatment 
have not been the population of focus although background factors such as age, race, 
education, income, and health insurance status have influenced medication-taking behaviors 
in other patient populations (Conn et at., 2015; Conn, Ruppar, Enriquez, & Cooper, 2015; 
Kilgore, Pulungan, Teigland, & Parente, 2016; Park, Howie-Esquivel, & Dracup, 2014; 
Whittle et al., 2016). 
 Thus, examining women’s perceptions regarding barriers to and facilitators of 
infertility MA will address an important knowledge gap in reproduction science research 
pivotal to generating possible solutions for overcoming MNA (Mahoney, 2018). This study  
incorporated a mixed-methods design to generate a comprehensive understanding of barriers 
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and facilitators that influence MA in this patient population. Study findings will serve as a 
first step to provide important information for developing innovative interventions to 
significantly improve MA behaviors and reduce unnecessary health care expenditure for 
infertility services. 
 The intent of the mixed methods design was to merge quantitative and qualitative 
data in order to generate broader insight concerning barriers to and facilitators of infertility 
MA by incorporating multiple perspectives (Creswell, 2015). The quantitative methods 
included questionnaires to assess barriers to MA and background (demographic) factors, and 
electronic monitoring of MA using the MEMS® (MEMS Track Cap; Westrock Switzerland) 
to assess MA behaviors. Although there is no gold standard measure of MA, electronic 
monitoring is considered by many investigators to be the best method available. MEMS® 
can accurately record medication-taking and make clear distinctions between the phases of 
MA—initiation, implementation, and discontinuation. This is done by integrating a small 
microcircuit into the MEMS® specialized bottle caps in such a way that the microcircuit 
records the time and date when medication doses are removed from the bottle. Electronic 
monitoring has been used to assess adherence behaviors in many clinical trials (Vrijens & 
Urquhart, 2012). The qualitative methods included conducting participant interviews to 
capture women’s perceived facilitators of MA and their personal experiences with infertility 
treatment.  
Study Purpose and Working Hypothesis 
 The purpose of this study was to identify perceived barriers to and facilitators of MA 
among women undergoing infertility treatment using a dynamic approach. This study was 
intended to advance human reproduction research and scientific ingenuity by generating 
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valuable information necessary to design and test innovative, cost-effective behavior change 
interventions to overcome infertility MNA at a time when expanding affordable health care 
access for infertility services has become a nationwide initiative. Following are specific 
aims, research questions, and working hypotheses of the study.  
Specific Aims, Research Questions, and Hypotheses 
Primary Aim/Research Question 
Primary Specific Aim: To identify barriers of and facilitators to MA among women 
undergoing infertility treatment. 
Primary Research Question: What do women undergoing infertility treatment 
perceive as barriers to and facilitators of MA that influence their medication-taking 
behaviors?  
Hypothesis 1. Women with a greater number of perceived barriers will demonstrate 
lower infertility MA scores than women with a lesser number of perceived barriers. 
Hypothesis 2. Women with a greater number of perceived facilitators will 
demonstrate higher adherence scores than women with a lesser number of perceived 
facilitators. 
Hypothesis 3. Differences will exist among perceived barriers and facilitators 
between women who are adherent and non-adherent. 
Secondary Aim/Research Question 
Secondary Specific Aim: To determine how background factors and personal 
experiences with infertility treatment influence women’s infertility medication-taking 
behaviors.  
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Secondary Research Question: What background factors and personal experiences 
with infertility treatment are associated perceived barriers of and facilitators to MA among 
women undergoing infertility treatment?  
Hypothesis 4. Differences will exist in women’s personal experiences with infertility 
treatment based on women’s age, race/ethnicity, level of education, income, and 
infertility insurance status. 
Hypothesis 5. Differences will exist between women who are adherent and non-
adherent by age, race/ethnicity, level of education, income, and infertility insurance 
status. 
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CHAPTER 2 
REVIEW OF LITERATURE 
 Chapter two represents a systematic review accepted for publication. Medication 
Adherence Among Women Undergoing Infertility Treatment: A Systematic Review to be 
published in International Journal of Women’s Health and Reproduction Sciences 
(Mahoney, Russell, & Cheng, 2019).  
 The reference list from this systematic review is incorporated into the references for 
the entire dissertation. 
Abstract 
Objectives: To investigate what is known regarding medication adherence in women 
undergoing infertility treatment. 
Materials and Methods: The data bases PubMed (1940 to 2017), Embase (1980 to 
2017), CINAHL (1982 to 2017), PsychINFO (1806 to 2017), and ProQuest dissertations 
were searched. Inclusion criteria were English-language: (1) prospective, (2) retrospective, 
(3) observational, (4) cross-sectional, (5) quasi-experimental, and (6) randomized controlled 
trial studies with medication adherence as a primary or secondary outcome in women with a 
diagnosis of infertility. Critical appraisal for study quality was assessed using Downs and 
Black Quality Checklist and STROBE guidelines. 
Results: Three articles from 1993 to 2011 were analyzed. Sample sizes varied from 
30 to 626 subjects with mean oral medication adherence rates ranging from 26% to 81% 
when used as first-line therapy. More frequent daily dosing was associated with lower 
adherence rates. Adherence was significantly lower when women were concerned about 
having side effects or reported three or more side effects versus one or two. Women with a 
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body mass index of <23 kg/m² or those who viewed medical treatment as convenient had 
higher adherence rates. None of the studies assessed medication adherence during controlled 
ovarian hyperstimulation (COH) cycles in conjunction with intrauterine insemination (IUI) 
or in vitro fertilization (IVF). 
Conclusions: Oral medication adherence rates are suboptimal when used alone as 
first-line therapy. Further investigation of medication-taking behaviors is warranted in future 
research trials involving injection medications and COH cycles associated with IUI and IVF 
cycles to strengthen clinical practice.  
Medication Adherence Among Women Undergoing Infertility Treatment: 
A Systematic Review 
Introduction 
Infertility is a significant health problem for women, estimated to affect 80 million 
people worldwide (Rubin & Phillips, 2012; Sharma, Biedenharn, Fedor, & Agarwal, 2013). 
In the United States (U.S.), approximately 16% of women of childbearing age are affected 
by infertility (Thoma et al., 2013). Many women undergo infertility treatment and are highly 
motivated to become pregnant (Chandra et al., 2014). Infertility treatment incorporates a 
variety of modalities to help women achieve pregnancy from minimally invasive to highly 
invasive procedures in conjunction with fertility medication. Treatment regimens can 
incorporate oral and/or injection medication for controlled ovarian hyperstimulation (COH) 
in combination with or without intrauterine insemination (IUI), as well as assisted 
reproductive technology (ART) procedures such as vitro fertilization (IVF) (American 
Society for Reproductive Medicine [ASRM], 2012b).  
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Women who opt to undergo any sort of infertility treatment are advised by healthcare 
providers to engage in self-managed lifestyle behaviors (e.g., healthy diet, adequate physical 
activity, smoking cessation, marijuana cessation, alcohol restrictions) and to follow 
prescribed fertility medication protocols to increase the chances of treatment success 
(Alvarez, 2015; Hassan & Killick, 2004; Klonoff-Cohen, 2005; Nafisehsadat, Kazemi, & 
Hasanzadeh. 2014; Rooney & Domar, 2014). Yet, adherence to health provider 
recommended lifestyle changes has been problematic (Domar, Conboy, Denardo-Roney, & 
Rooney, 2012; Domar, Rooney, Milstein, & Conboy, 2015; Gormack et al., 2015; Rooney & 
Domar, 2018; Schilling, Toth, Rösner, Strowitzki, & Wischmann, 2012). In fact, negative 
lifestyle behaviors have contributed to lower pregnancy rates for women undergoing IVF 
(Kasum et al., 2017; Klonoff-Cohen, Lam-Kruglick, & Gonzalez, 2003; Klonoff-Cohen, 
Natarajan, & Chen, 2006; Klonoff-Cohen, Natarajan, Marrs, & Yee, 2001; Rittenberg et al., 
2011; Rossi et al., 2011). This raises concerns regarding the extent to which women adhere 
to fertility medications while receiving treatment. 
 Adherence to prescribed medication is important for achieving targeted health 
outcomes (Vrijens et al., 2012). Medication non-adherence is recognized as a prevalent 
global problem in the general population, with adherence rates averaging 50% worldwide 
(Sabaté & World Health Organization, 2003). Nonetheless, the medication-taking behavior 
of women receiving infertility treatment has not been adequately assessed. This may be due 
to a belief that medication adherence is optimal in this patient population, particularly with 
high stakes procedures like IVF. After all, infertility treatment has resulted in successful 
pregnancies for many women, though most often after repeated treatments. While a 
woman’s likelihood of pregnancy with infertility treatment decreases as she ages (35 years 
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and older), younger women (under 35 years) undergoing ART in the U.S. average 38% 
pregnancy rates for each treatment cycle (National Center for Chronic Disease Prevention 
and Health Promotion, 2017; Society of Assisted Reproductive Technology, 2016). 
Infertility treatment regimens are often complex and can impede women’s daily lives 
(Boivin et al., 2012). Treatment cycles incorporate oral and/or injection routes. Medication 
schedules range from daily to multiple daily doses that are very time sensitive in nature 
(Smith, Grimm, & Schwegel, 2012). Failure to correctly take the medication during a 
treatment cycle decreases the likelihood of the medication having its intended effect on 
reproductive hormones and ovarian follicular development, ultimately driving up healthcare 
costs for repeated treatments (Katz et al., 2011; Noorhasan et al., 2008).  
Adherence can be defined as “the extent to which a person’s behavior—medication 
taking, following a diet, and/or executing lifestyle changes corresponds with agreed 
recommendations from a health care provider” (Sabaté & World Health Organization, 2003, 
p. 3). In infertility literature, medication adherence is not well defined during non-ART 
cycles such as IUI. With respect to ART, adherence has referred to the continuation of ART 
cycles (including medication adherence) recommended by the infertility provider until 
pregnancy is attained or until there are provider recommendations to discontinue treatment 
(Gameiro, Verhaak, Kremer, & Boivin, 2013). Therefore, existing research has concentrated 
on ART cycle discontinuation rates rather than medication-taking patterns (Gameiro, 
Boivin, Peronace, & Verhaak, 2012; Gameiro et al., 2013).  
 Medication adherence has three distinct components: initiation, implementation, and 
discontinuation (Vrijens et al., 2012). Initiation is when a patient takes the first dose of a 
prescribed medication. Implementation refers to the degree to which the patient’s actual 
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medication usage corresponds to the prescribed medication regimen. Discontinuation occurs 
when the next scheduled dose to be taken is omitted and no more medication is taken after 
this point. Thus non-adherence occurs with late or no initiation of the prescribed medication, 
suboptimal implementation of the prescribed regimen, or early discontinuation (Vrijens et 
al., 2012).  
 Women with infertility are a population challenged by physical, psychological, 
emotional, and financial demands that accompany treatment, and some women have 
reported taking fertility medication incorrectly (Brod et al., 2009; Huisman, Raymakers, & 
Hoomans, 2009; Markle, King, Martin, Kutteh, & Ke, 2002; Noorhasan et al., 2008). Yet, 
researchers have not established a methodological process to monitor medication adherence 
with this group of women. Nor has there been attention directed to factors to improve 
medication-taking behaviors in this population. Moreover, no prior review has explored the 
medication adherence patterns of women undergoing any type of infertility treatment. The 
aim of this review is to determine medication adherence rates in women undergoing 
assistive reproductive treatment. Study questions include: (1) What are fertility medication 
adherence rates? and (2) What are the predictors of and barriers to medication adherence 
among women receiving infertility treatment? Through identifying patterns, predictors, and 
barriers related to medication adherence in women with infertility, clinical interventions can 
be strengthened. By improving the quality of future medication adherence research, 
treatment clinical outcomes could be improved, further decreasing the likelihood of repeated 
failed cycles for non-adherence while ultimately reducing overall health care expenditure.  
11 
Methods 
Literature Search Strategy 
The systematic review was conducted according to the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis) standards (Moher, Liberati, 
Tetzlaff, & Altman, 2009). A search was conducted to identify studies in which medication 
adherence among infertile women undergoing infertility treatment was investigated using 
PubMed (1940 to 2017), Embase (1980 to 2017), Cumulative Index of Nursing and Allied 
Health Literature (CINAHL) (1982 to 2017), PscyhINFO (1806 to 2017), and ProQuest 
dissertations. Combinations of the following terms were used: “adherence,” “compliance,” 
“persistence,” “concordance,” “non-adherence,” “non-adherence,” “noncompliance,” “non-
compliance,” “infertil*,” “fertil*,” “subfertil*,” “infecund*,” “subfecund*,” “barren,” 
“sterility,” “infertility treatment,” “fertility treatment,” “in vitro fertilization,” “intrauterine 
insemination,” “pharmaceutic*,” “prescript*,” “medicat*,” “medicine,” “medicines,” 
“drug,” “drugs,” “women,” “woman,” and “female.” 
Inclusion/Exclusion Criteria  
Inclusion criteria were: (1) prospective, retrospective, observational, cross-sectional, 
quasi-experimental, and randomized controlled trial studies; (2) female participants aged 18 
to 44 years with a diagnosis of infertility documented in the medical record; and (3) 
medication adherence as the primary or secondary study outcome. Participants age 18 to 44 
were included because this age range is representative of women who seek infertility 
treatment (Chandra et al., 2014). Participants younger than age 18 were excluded because 
they are not a population that seeks infertility services. Participants beyond the age of 44 
were excluded because reproductive potential is reduced with advancing age (ASRM, 
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2012a). Studies were also excluded also if they were not published in the English language. 
The PRISMA Flow Diagram for the study selection process is displayed in Figure 2.1. 
Formal approval by an ethical review committee was not required by the university to 
conduct this review. 
 
Figure 2.1 PRISMA 2009 Flow Diagram 
Data Extraction 
Data extraction was performed and agreed upon by two independent reviewers (DM 
and CR) using a structured data collection sheet. Data extraction included 
author/year/design, purpose, sample/setting, intervention, measures, results, strengths, and 
limitations. A summary of data extraction is presented in Table 2.1. 
PRISMA Flow Diagram 
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Quality Assessment 
Critical appraisal was assessed by two independent reviewers (DM and CR) using 
the Downs and Black (1998) checklist for assessing methodological quality of randomized 
and non-randomized studies and Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines (von Elm et al., 2008). The STROBE guidelines were 
used to assess the quality of one study (Li et al., 2011) because the Downs and Black (1998) 
criteria were not applicable for non-interventional studies. After discussion, there was 
complete agreement on study quality between both reviewers. The Downs and Black (1998) 
quality checklist consists of 26 items spread across five subscales including (1) reporting (9 
items), (2) external validity (3 items), (3) bias (7 items), (4) confounding (6 items), and (5) 
power (1 item). Items are scored individually with a maximum total score of 32 indicating 
highest quality. This tool has demonstrated high internal consistency (Kuder-Richardson test 
= 0.89), good test-retest reliability (0.88), good criterion validity (0.89), and inter-rater 
reliability (0.75) (Downs & Black, 1998). STROBE guidelines are designed as criteria for 
reporting observational studies; however, these guidelines have been used to assess 
methodological rigor of published studies (Matteson & Russell, 2013). Quality reporting of 
the individual studies included in this review is shown in Tables 2.2 and 2.3.  
Results 
Five studies, published from 1990 to 2011, met the inclusion criteria. However, two 
of the five studies were excluded after three studies, conducted by the same authors (Kruse 
et al., 1990, 1991, 1993) revealed strong similarities of sample characteristics (e.g., age, 
years of infertility, study location, intervention, authors), raising suspicion of possible 
analysis of the same sample. Therefore, only results from the most recent study of these 
14 
three (Kruse et al., 1993) was used in this review analysis to ensure validity of study 
findings. The two earlier studies (Kruse et al., 1990, 1991) are shaded in Table 2.1 and were 
not included as individual study contributors in the analysis. 
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Table 2.1 
Summary of Extraction Data 
Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
Li, He, Yang, Yin, and 
Xu (2011). Prospective, 
nonrandomized, 
observational, cross-
sectional 
 
Investigate the 
medication 
compliance of 
infertile patients 
with Polycystic 
Ovarian 
Syndrome 
(PCOS). 
 
Assess factors 
that might 
contribute to 
noncompliance in 
order to provide a 
basis for clinical 
treatment, 
specialist 
consultation, and 
health education. 
N= 90 
Age: x=28.71± 
3.63 years 
20-25 (n=17) 
26-30 (n=45) 
≥31 (n=28) 
 
BMI: 
x=24.0±4.34 
kg/m²  
<23 (n=38, 23-
25 (n=18), ≥ 25 
(n=34) 
 
Race or ethnic 
group: NR 
 
Length of time 
attempting to 
conceive: ≥ 1 
year 
 
No history of 
pregnancy: 
68.9% 
 
Prior history of 
infertility 
treatment: 
34.4% 
 
 
 None 1) 
Questionnaire 
consisting of 3 
questions 
derived from 
the Morisky-
Green test and 
1 question 
addressing 
weight loss 
based on the 
principles of 
PCOS. 
 
2) 
Questionnaire 
with contents 
assessing (a) 
demographic 
information, (b) 
disease 
diagnostic 
information, 
and (c) self-
factors 
including 
personal, 
medical, 
economic, and 
social 
experiences and 
concerns 
Primary findings: 
Overall compliance 
to treatment: 23 
(25.6%)  
Compliance to 
medications: 
contraceptive 
drugs-31 (48.4%), 
anti-insulin 
resistance drugs-28 
(52.8%), 
clomiphene-
15(60%), 
traditional Chinese 
medicine-3(30%). 
 
BMI (P=0.040), 
convenience of 
medical treatment 
(P=0.012), and 
concerns about 
adverse drug 
effects (P=0.043) 
significantly 
affected 
compliance to 
treatment.  
 
Secondary 
findings: NR 
Strengths: Sample inclusion 
criteria clearly specified, 
moderate sample size. 
Adherence measures 
adequately described. 
Statistical methods 
appropriate. 
 
Limitations: External review 
of study by an ethics review 
board not reported. Actual 
compliance rates not 
reported, only categorized as 
good compliance rates. 
Convenience sampling and 
nonrandomized. 
Race/ethnicity of sample not 
reported. Potential for 
sampling bias and sampling 
homogeneity limiting 
generalizability of study 
results. . Potential for a lower 
reliability and accuracy in 
participant self-reporting on 
survey questionnaires. 
Potential for inaccuracy in 
content validity on second 
questionnaire. No theoretical 
framework basis addressed.  
 
 
Table continues 
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Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
Self-pay for 
medical 
expenses: 88.9% 
 
Postsecondary 
education: 
57.8%  
 
Setting: 
Reproductive 
Medical Center 
in China 
surrounding 
PCOS. 
 
Timing: 
baseline, study 
lasted for 6 
months 
McGovern et al. (2008). 
Retrospective, 
randomized controlled 
trial 
 
Examine 
mediation 
adherence in the 
metformin-
containing arms 
of the primary 
study to 
determine 
whether 
participants 
within the 
expected range 
for similar trials.  
N=626 
metformin 
group: n=208, 
clomiphene 
group: n=209, 
combination 
group: n=209 
 
Age (years): 
metformin group 
28.1± 4.0, 
clomiphene 
group 27.9± 4.0, 
combination 
group 28.3 ± 4.0 
 
BMI: metformin 
group 35.6 
kg/m² ± 8.5, 
clomiphene 
group 36.0± 8.9, 
combination 
group 34.2 ± 8.4 
 
Metformin 
Group: 
2000mg 
daily plus 
clomiphene 
placebo 
 
Clomiphen
e Group: 
50, 100, or 
150 mg 
daily for 5 
days per 
cycle plus 
metformin 
placebo. 
 
Combined 
Group: 
metformin 
2000mg 
daily plus 
clomiphene 
50, 100, or 
150 mg 
Pill counts used 
to assess 
adherence by 
percentage of 
recommended 
tablets not in 
the returned 
bottles by 
counting the 
remaining 
tablets.  
 
Timing: 
baseline and 
monthly for up 
6 cycles or 6 
months, pill 
counts from 
returned bottles 
performed 
monthly. 
Primary findings: 
Overall median 
adherence rate was 
81%. Median 
adherence rates 
were 81.6% in 
metformin group 
and 81.7% in 
combination group. 
No significant 
(P=0.80) difference 
in medication 
adherence between 
metformin group 
and combined 
group. 
 
Ovulatory rates 
were low in the 
metformin group 
across all levels of 
adherence. 
 
Secondary 
findings: Median 
Strength: Sample 
randomization and control, 
and blinding present,  
Sample large and 
heterogeneous. Sampling 
bias minimized by 
stratification according to the 
study site and the presence or 
absence of previous exposure 
to either of the study drugs. 
Instruments were adequately 
described. Statistical 
methods appropriate. 
 
Limitations: Study setting 
not adequately described. A 
total of 176 participants 
dropped of study. Medication 
adherence not originally 
reported in primary study. 
Discrepancy between sample 
size of metformin arm 
(n=195) in secondary study  
 
 
Table continues 
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Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
Race or ethnic 
group: 
 
Metformin 
group-Caucasian 
67.6%, Hispanic 
29.3%, Black 
19.3%, Asian 
2.4%, Native 
American 
13.0%: 
Clomiphene 
group-Caucasian 
70.7%, Hispanic 
25.4%, Black 
17.8%, Asian 
2.4%, Native 
American 
10.1%; 
Combination 
group- 
Caucasian 
71.2%, Hispanic 
23.9%, Black 
15.4%, Asian 
3.4%, Native 
American 11.5% 
 
Length of time 
attempting to 
conceive 
(months): 
metformin group 
39.0± 31.9, 
clomiphene 
group 41.4± 
39.4, 
daily for 5 
days per 
cycle. 
 
adherence for 
clomiphene group 
was 100% in 
clomiphene and 
combined groups.  
and sample size of 
metformin arm (n=208) 
reported in primary study. 
Pill counts less reliable in 
assessing medication 
adherence if participants 
removed pills out of bottle 
that were not taken. Primary 
study was not designed to 
investigate adherence 
systematically. No 
theoretical basis addressed.  
Table continues 
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Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
combination 
group 40.7 ± 
36.0 
Prior history of 
infertility 
treatment: 
metformin group 
53.4%, 
clomiphene 
group 55.5%, 
combination 
group 55.5% 
Self-pay for 
medical 
expenses: NR 
Postsecondary 
education: NR 
Setting: Multi-
centers, location 
unknown. 
 
Kruse, Eggert-Kruse, 
Rampmaier, 
Runnebaum, and Weber 
(1993). Prospective, 
cross-sectional, 
randomized 
 
To examine the 
relationship 
between adverse 
reactions and 
patient 
compliance in 
women with 
primary 
infertility. 
N=61 
Age: x=30.4±4.4 
years (range, 21-
39 years) 
 
BMI: NR 
 
Race or ethnic 
group: NR 
 
Length of time 
attempting to 
conceive: 4.5± 
2.7 years (range, 
9 months-19 
years) 
Ethinylestra
-diol at 
40µg twice 
daily or 
20µg four 
times daily 
for 7 days 
Medication 
Event 
Monitoring 
System used to 
evaluate 
percentage of 
prescribed 
doses taken 
during the 
period. 
(administrative 
compliance-
container 
openings 
recorded during 
the period 
Primary findings:  
Overall mean 
compliance was 
75.7%. 
Administration 
compliance ranged 
from 7-143% and 
regimen 
compliance ranged 
from 0-100% for 
twice a day dosing. 
Administration 
compliance ranged 
from 14-136% and 
regimen 
compliance ranged 
Strengths, randomization 
present, moderate sample 
size. Adherence measures 
adequately described. Key 
variables were 
operationalized.  
 
Limitations: Limited review 
of literature to provide 
synthesis on the existing 
evidence of medication 
adherence. External review 
of study by an ethics review 
board not reported. Method  
 
 
Table continues 
  
1
9
 
Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
 
No history of 
pregnancy: NR 
 
Self-pay for 
medical 
expenses: NR 
 
Postsecondary 
education: NR 
 
Setting: 
Infertility Unit 
of Women’s 
Hospital, 
Heidelberg, 
Germany 
divided by the 
prescribed 
number of 
doses during 
the period) and 
adherence to 
the prescribed 
dose schedule 
(regimen 
compliance-the 
number of days 
in which two 
openings for 
twice daily 
regimen or four 
openings for 
four times per 
daily regimen) 
Timing: daily 
for 7 days 
 
Standardized 
questionnaire to 
assess for 
adverse drug 
reactions which 
asked 
participants to 
rate symptoms 
which they 
attributed to the 
drug as mild, 
moderate, or 
severe 
 
Timing: once 
after 
from 0-100% for 
four times per day 
dosing. 
 
Mean 
administration 
compliance: 85% 
for twice a day 
dosing and 65% for 
four times per day 
dosing (P<0.05). 
 
Mean regimen 
compliance: 62% 
for twice a day 
dosing and 34% for 
four times per day 
dosing (P<0.005). 
 
No significant 
difference in 
compliance 
comparing 
participants with or 
without adverse 
drug reactions.  
 
Compliance was 
significantly lower 
(P< 0.05) when 
participants 
reported three or 
more adverse drug 
reactions versus 
one or two: 54% 
versus 84% in 
administrative 
of sample randomization 
design not addressed. No 
report on avenues used to 
minimize sampling bias. 
Sample inclusion criteria not 
clearly specified. Limited 
sample demographics. 
Ethnicity not reported-
potential of sample 
homogeneity. Potential for a 
lower reliability and 
accuracy in participant self-
reporting on questionnaires. 
Statistical methods used 
were not adequately 
described. No theoretical 
framework basis addressed.  
 
Table continues 
  
2
0
 
Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
completing 7 
days of 
ethinylestradiol 
compliance and 
31% versus 58% in 
regimen 
compliance). 
 
Compliance was 
lower in 
participants with 
nausea and 
vomiting compared 
to those without 
these symptoms: 
59% versus 91% in 
administrative 
compliance and 
34% versus 66% in 
regimen 
compliance (P< 
0.005). 
 
Compliance was 
lower with 
moderate or severe 
side effects 
compared to mild 
side effects: 48% 
versus 85% in 
administrative 
compliance and 
25% versus 59% in 
regimen 
compliance (P< 
0.005). 
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Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
Kruse, Eggert-Kruse, 
Rampmaier, 
Runnebaum, and Weber 
(1991). Prospective, 
cross-sectional, 
randomized 
 
To investigate 
patient 
compliance with 
two different 
dosage schedules 
of 
ethinyloestradiol 
20µg four times 
daily versus 40µg 
two times daily.  
N=65 
Age: x=29.9 
years (range, 21-
39 years) 
 
BMI: NR 
Race or ethnic 
group: NR 
 
Length of time 
attempting to 
conceive: 4.3 
years (range 9 
months to 19 
years) 
 
No history of 
pregnancy: NR 
 
Self-pay for 
medical 
expenses: NR 
 
Postsecondary 
education: NR 
 
Setting: 
Infertility Unit 
of Women’s 
Hospital, 
Heidelberg, 
Germany 
Ethinyloest
r-adiol at 
40µg twice 
daily or 
20µg four 
times daily 
for 7 days 
Medication 
Event 
Monitoring 
System used to 
evaluate 
percentage of 
container 
openings 
(recorded pill 
openings 
during the 
period divided 
by the 
prescribed 
number of 
doses during 
the period 
multiplied by 
100) and 
adherence to 
the prescribed 
dose schedule 
(regimen 
compliance-the 
number of days 
in which two 
openings for 
twice daily 
regimen or four 
openings for 
four times per 
daily regimen) 
 
Timing: daily 
for 7 days 
 
 
Mean overall 
compliance was 
75.7% (range 7.1 -
143%). 
Mean compliance 
with twice daily 
dosing was 85% 
compared to 67% 
with four times per 
day dosing 
(P<0.05) 
Regimen 
compliance: 63% 
for twice a day 
dosing and 36% for 
four times per day 
dosing (P<0.005). 
 
Strengths, randomization 
present, moderate sample 
size. Adherence measures 
adequately described. Key 
variables were 
operationalized. To minimize 
attrition, participants who 
failed to return MEMS 
bottles were emailed 
reminders. Statistical 
methods appropriate.  
 
Limitations: Limited review 
of literature to provide 
synthesis on the existing 
evidence of medication 
adherence. External review 
of study by an ethics review 
board not reported. Method 
of sample randomization 
design not addressed. Sample 
inclusion criteria not clearly 
specified. No discussion of 
power analysis to estimate 
sample size. Limited sample 
demographics. Potential for 
limitation of study finding 
generalizability. Ethnicity 
not reported-potential of 
sample homogeneity. No 
theoretical framework basis 
addressed. 
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Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
Kruse, Eggert-Kruse, 
Rampmaier, 
Runnebaum, and Weber 
(1990). Prospective, 
cross-sectional, 
randomized 
To investigate 
patient 
compliance with 
ethinyl-oestradiol 
therapy of 20 µg 
four times daily. 
N=30 
Age: x=28.8 
years (range, 21-
36 years) 
 
BMI: NR 
Race or ethnic 
group: NR 
 
Length of time 
attempting to 
conceive: 3.9 
years (range 9 
months to 8 
years) 
 
No history of 
pregnancy: NR 
 
Self-pay for 
medical 
expenses: NR 
 
Postsecondary 
education: NR 
 
Setting: 
Infertility Unit 
of University 
Women’s 
Hospital 
Ethinyl-
oestradiol 
therapy of 
20 µg four 
times daily. 
Medication 
Event 
Monitoring 
System. 
Compliance 
data was 
obtained as 
listings of the 
time and date 
of individual 
bottle openings 
and closings, 
duration of 
openings, and 
the hours since 
previous dose. 
Compliance 
was defined as 
the number of 
doses taken 
during period 
divided by the 
number of 
prescribed 
doses during 
period 
multiplied by 
100.  
 
Timing: daily 
for 7 days 
 
Interview 
regarding 
adverse drug 
effects which 
consisted of 
Mean overall 
compliance was 
64.9% (range 14.3 
to 136%).  
 
Mean adherence to 
prescribed QID 
regimen was 34.3% 
(range 0-114%). 
 
Sixteen of the 30 
participants 
reported adverse 
drug reaction on 
response open-
question or 
spontaneously.  
 
Twenty-four 
participants 
reported side 
effects on 
standardized 
questionnaire. 
Seventy-nine 
percent of the 
symptoms were 
rated as being mild.  
 
In participants who 
had a compliance 
rate >65%, 
adherence rate 
correlated with 
reported adverse 
drug reactions 
Strengths: randomization 
present. Adherence measures 
adequately described. Key 
variables were 
operationalized. Addressed 
accuracy of MEMS. To 
minimize attrition, 
participants who failed to 
return MEMS bottles were 
emailed reminders. All 
participants were interviewed 
by same investigator. To 
reduce confounding 
variables, only participants 
who were not taking other 
medications during study 
were included. Statistical 
methods appropriate. 
 
Limitations: Small sample 
size. Limited review of 
literature to provide 
synthesis on the existing 
evidence of medication 
adherence. External review 
of study by an ethics review 
board not reported. Method 
of sample randomization 
design not addressed. Sample 
inclusion criteria not clearly 
specified. No discussion of 
power analysis to estimate 
sample size. Limited sample 
demographics. Potential for 
limitation of study finding  
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Author/Year/Design Purpose Sample/Setting Intervention 
 
Measures Results Strengths/Limitations 
one open 
question 
followed by a 
standardized 
questionnaire 
rating adverse 
symptoms as 
mild, moderate, 
or severe.  
 
Timing: 
Immediately 
after the 7-day 
ethinyl 
oestradiol 
regimen 
completed 
inversely (r=0.71; 
P<0.01). 
 
The lower the 
compliance rate, 
the more adverse 
drug reactions were 
reported (no r or P 
value provided). 
 
Compliance was 
positively 
correlated with 
duration of 
infertility (r=0.44; 
P<0.05). 
generalizability. Ethnicity 
not reported-potential of 
sample homogeneity. 
Potential for a lower 
reliability and accuracy in 
participant self-reporting on 
questionnaires. No 
theoretical framework basis 
addressed.  
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Table 2.2 
Downs and Black Checklist 
Study 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Quality 
 Score 
McGovern 
et al. 
(2008) 
1 1 1 1 1 1 0 1 1 0 0 1 0 1 1 1 1 1 0 0 1 1 1 0 0 1 5 23 
Kruse et 
al. (1993) 
0 0 1 1 0 1 1 1 0 0 0 0 1 0 0 1 1 1 1 1 1 0 1 0 0 0 1 14 
 
Key:  
Reporting: “Yes=1,” “No=0”  
1. Is the hypothesis /aim /objective of the study clearly described?  
2. Are the main outcomes to be measured clearly described in the Introduction or Methods section?  
3. Are the characteristics of the patients / samples included in the study clearly described?  
4. Are the interventions of interest clearly described? “Yes=2,” “Partially=1”, “No=0” 
5. Are the distributions of principal confounders in each group of subjects to be compared clearly described? “Yes=1,” “No=0”  
6. Are the main findings of the study clearly described?  
7. Does the study provide estimates of the random variability in the data for the main outcomes?  
8. Have all important adverse events that may be a consequence of the intervention been reported?  
9. Have the characteristics of patients lost to follow-up been described?  
10. Have actual probability values been reported (e.g., 0.035 rather than <0.05) for the main outcomes except where the probability 
value is less than 0.001? 
 
External validity: “Yes=1,” “No=0,” “Unable to determine=0”  
11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited?  
12. Were those subjects who were prepared to participate representative of the entire population from which they were recruited?  
13. Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?  
 
Internal validity-bias: “Yes=1,” “No=0,” “Unable to determine=0”  
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14. Was an attempt made to blind study subjects to the intervention they have received? 
15. Was an attempt made to blind those measuring the main outcomes of the intervention? 
16. If any of the results of the study were based on “data dredging” was this made clear? 
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the 
time period between the intervention and outcome the same for cases and controls?  
18. Were the statistical tests used to assess the main outcomes appropriate? 
19. Was compliance with the intervention/s reliable? 
20.Were the main outcome measures used accurate (valid and reliable)?  
 
Internal validity -confounding (selection bias): “Yes=1,” “No=0,” “Unable to determine=0”  
21. Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) 
recruited from the same population? 
22. Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) 
recruited over the same period of time?  
23. Were study subjects randomized to intervention groups?  
24. Was the randomized intervention assignment concealed from both patients and health care staff until recruitment was complete and 
irrevocable?  
25. Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?  
26. Were losses of patients to follow-up taken into account?  
 
Power  
27. Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to 
chance is less than 5%? Sample sizes have been calculated to detect a difference of x% and y%.  
Size of smallest intervention group  
1. A 1<n1 0  
2. B n1-n2 1  
3. C n3-n4 2  
4. D n5-n6 3  
5. E n7-n8 4  
6. F n8+ 5  
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Table 2.3 
STROBE Quality Assessment  
 Item 
No Recommendation 
Li et al, 
(2011) 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Yes 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found Yes 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Yes 
Objectives 3 State specific objectives, including any pre-specified hypotheses No 
Methods  
Study design 4 Present key elements of study design early in the paper Yes 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-
up, and data collection 
Yes 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants Yes 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
No 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). 
Describe comparability of assessment methods if there is more than one group 
Yes 
Bias 9 Describe any efforts to address potential sources of bias No 
Study size 10 Explain how the study size was arrived at No 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why 
No 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding Yes 
(b) Describe any methods used to examine subgroups and interactions No 
(c) Explain how missing data were addressed No 
(d) If applicable, describe analytical methods taking account of sampling strategy No 
(e) Describe any sensitivity analyses No 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed 
Yes 
(b) Give reasons for non-participation at each stage Yes 
(c) Consider use of a flow diagram No 
Descriptive data 14* (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on 
exposures and potential confounders 
Yes 
Table continues 
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 Item 
No Recommendation 
Li et al, 
(2011) 
(b) Indicate number of participants with missing data for each variable of interest No 
Outcome data 15* Report numbers of outcome events or summary measures Yes 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 
95% confidence interval). Make clear which confounders were adjusted for and why they were included 
Yes 
(b) Report category boundaries when continuous variables were categorized No 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
period 
No 
Other analyses 17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses No 
Discussion  
Key results 18 Summarize key results with reference to study objectives Yes 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
Yes 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
Yes 
Generalizability 21 Discuss the generalizability (external validity) of the study results Yes 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 
original study on which the present article is based 
No 
 28 
Characteristics of Study Participants 
The total sample size was 777 participants. Individual study sample sizes ranged 
from 30 to 626 subjects with mean ages ranging between 28 and 30 years. Only one study 
reported on participant race/ethnicity with the majority (68%) being of Caucasian ancestry 
(McGovern et al., 2008). Mean body mass index (BMI) ranged from 24.0 to 36.6 kg/m² (Li 
et al., 2011; McGovern et al., 2008). Length of time attempting to conceive varied from one 
year to more than four years (Kruse et al., 1993; Li et al., 2011). Most of the participants (n= 
716) were infertile women with polycystic ovary syndrome (PCOS).  
Study Location and Practice Setting 
Studies were conducted in the United States (McGovern et al., 2008), Germany 
(Kruse et al., 1993), and China (Li et al., 2011). One study addressed the type of payment 
for services, reporting 88.9% of participants were self-pay (Li et al., 2011). In two studies, 
34.4% to 55% had undergone prior infertility treatment, and 31.1% to 36.8% reported a 
previous pregnancy (Li et al., 2011; McGovern et al., 2008). 
Study Purpose and Study Type 
In all three studies, medication adherence was examined as first-line therapy. None 
of the studies assessed adherence associated with IUI or IVF cycles. Two of the three studies 
(Kruse et al., 1993; McGovern et al., 2008) shared a common purpose to examine oral 
medication adherence, while the remaining study (Li et al., 2011) evaluated the combination 
of adherence to oral medication and weight loss recommendations. One study (Li et al., 
2011) was a prospective, observational design; one study (Kruse et al., 1993) was 
prospective and randomized without a control group; and the remaining study (McGovern et 
 29 
al., 2008) was a randomized controlled trial with medication adherence examined 
retrospectively.  
Medication Adherence and Theoretical Framework  
Researchers in two of the three studies measured medication adherence using 
objective measures, which were medication event monitoring (Kruse et al., 1993) and pill 
counts (McGovern et al., 2008). The remaining study (Li et al., 2011) measured medication 
adherence using a subjective measure (brief medication questionnaire). Mean adherence 
rates ranged from 26% to 81% (Li et al., 2011 & McGovern et al., 2008). There was no 
reporting on specific types of non-adherence (e.g., initiation, execution, persistence). None 
of the studies used a supporting theoretical framework.  
Predictors and Barriers Related to Medication Adherence 
In two of three studies researchers investigated possible factors that contributed to 
treatment non-adherence (Kruse et al., 1993; Li et al., 2011). Medication adherence was 
significantly lower when participants were concerned about having side effects or reported 
three or more side effects versus one or two (Kruse et al., 1993; Li et al., 2011). Participants 
who had a BMI <23 kg/m² or who viewed medical treatment as convenient had higher 
adherence rates (Li et al., 2011). The more frequent the medication dosing per day, the lower 
the adherence rates (Kruse et al., 1993; Li et al., 2011; McGovern et al., 2008). 
Discussion 
As the first of its kind, this systematic review was conducted to investigate 
medication adherence among women undergoing infertility treatment. Only three studies 
met criteria for inclusion in this review. While an abundance of literature exists on 
adherence to lifestyle recommendations in women receiving infertility treatment, interest in 
 30 
studies on medication-taking behaviors has been overlooked 4; Zarinara et al., 2016). This 
review revealed that first-line oral medication adherence rates have a wide variation (26% to 
81%). None of the studies assessed injection medication adherence nor medication-taking 
patterns during COH cycles associated with IUI and IVF. One could assume that women 
taking first-line oral medications would not have as high stakes—time investment, financial 
commitment, medical risks—as women undergoing more advanced therapy, which could 
influence adherence behaviors. However, this review provided evidence that oral medication 
adherence rates are consistent with general adherence rates in the literature that average 
50%.  
One of the three studies in this review addressed a lifestyle factor combined with 
medication adherence behavior. Li and colleagues (2011) examined treatment adherence to 
oral medications and weight loss recommendations within a subpopulation of infertile, obese 
women with PCOS. Obesity is a lifestyle management factor known to reduce infertility 
treatment success, and this review found that women who were not obese demonstrated 
better oral medication adherence (Bellver, Busso, Pellicer, Remohí, & Simón, 2006; Pinborg 
et al., 2011; Rittenberg et al., 2011). Thus, obese women may be at higher risk for multiple 
non-adherence behaviors (Mutsaerts, Kuchenbecker, Mol, Land, & Hoek, 2013). A recent 
study showed that 40% of women seeking infertility treatment actively engaged in at least 
four unfavorable lifestyle-related behaviors that could negatively influence reproductive 
outcomes (Piché, Babineau, Robitaille, Lachance, & Ruchat, 2018). This novel systematic 
review has provided groundbreaking evidence that oral infertility medication adherence 
behaviors are also unfavorable. The combination of medication non-adherence and negative 
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lifestyle behaviors present a new conundrum that has not been adequately addressed in prior 
literature for this population.  
Medication side effects and dosing frequency were observed as potential barriers to 
adherence (Kruse et al., 1993; Li et al., 2011, McGovern et al., 2008). Understanding 
potential barriers is important for optimizing adherence during infertility treatment cycles. 
As scientists continue to advance strategies for improving innovative reproductive 
procedures, technology can only be effective if medication protocols are followed. So far, 
the relationship between fertility medication non-adherence behaviors and reproductive 
outcomes (canceled cycles, clinical pregnancies, live birthrates) has not been well 
documented in the literature. Markle et al. (2002) found that failure of women to correctly 
self-administer injection medication resulted in lower pregnancy rates.  
Adherence to injection medication was not measured in any of the studies from this 
review although these medications have been problematic for other patient populations such 
as diabetes and those with multiple sclerosis (Capoccia, Odegard, & Letassy, 2016; 
Giovannoni, Southam, & Waubant, 2012). Prescribed injectable regimens are commonly 
used in infertility treatment regimens. They are available in either single or multiple-dose 
vials requiring the client to withdraw the medication into a syringe prior to administration or 
administer preloaded, multiple-dose self-injection pens. Women have reported concerns 
about self-administering injections correctly (Brod et al., 2009; Huisman et al., 2009). Some 
women have made medication errors but failed to report them to the infertility nurse or 
physician due to either considering the error insignificant or fearing a negative reaction from 
the provider (Huisman et al., 2009). One study reported a case in which the client knowingly 
self-administered less than the prescribed dosage of injection medication in order to save on 
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medication cost (Noorhasan et al., 2008). The studies in this review did not examine 
women’s perspectives on taking fertility medication. However, discrepancies between 
healthcare providers’ and clients’ perspectives on injection medication-taking behaviors 
have been explored. Providers reported concern about client adherence to self-injection 
medications, yet they were surprised to find that women were taking incorrect medications, 
administering incorrect doses, and self-injecting medication incorrectly (Boivin et al., 2012; 
Brod et al., 2009). 
The infertility healthcare environment along with prescribed medication protocols 
seem to overwhelm women who undergo infertility treatment. Li et al. (2011) reported that 
women who viewed their infertility treatment as convenient demonstrated higher adherence 
rates compared to those who found the treatment inconvenient. Treatment burden has been 
an ongoing problem for this patient population (Boivin et al., 2012; Brod et al., 2009; 
Huisman, , 2009). In fact, the inconvenience of frequent medication injections and total 
length of treatment are central contributors to infertility treatment strain (Brod et al., 2009). 
In addition, the clinic environment has been shown to amplify treatment burden and impact 
women’s decisions to end treatment. Factors reported by women include lack of continuity 
of care, negative health provider attitudes, ineffective communication with clinic staff, and 
insufficient time for questions (Boivin et al., 2012). A patient-centered care model has 
gained notable recognition as an indicator of high-quality infertility services (Aarts et al., 
2012; Gameiro, Canavarro, & Boivin, 2013; Huppelschoten et al., 2015). Thus, 
understanding the relationship between quality of care and respective attitudes and behaviors 
toward medication adherence would prove noteworthy. 
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Experts have begun an initiative to identify avenues for overcoming barriers to 
infertility treatment by improving care for women both nationally and internationally 
(ASRM, 2015). The U.S. health insurance environment has been an obstacle to gaining 
coverage for infertility services (National Conference of State Legislatures, 2014). Only 15 
states have passed laws that require insurers to either cover or offer coverage for infertility 
diagnosis and treatment, although some employers do provide infertility coverage in non-
mandated states (National Conference of State Legislatures, 2014). The American Society 
for Reproductive Medicine released a white paper on the current state of patient access to 
fertility care in the U.S. which outlined steps to improve access to care that include 
infertility coverage (ASRM, 2015). As this initiative moves forward, the urgency to redirect 
the focus on barriers to medication adherence may become a greater priority.  
The focus in the general medication adherence literature has been on interventions to 
improve quality of life, increase life expectancy, and reduce healthcare costs in chronic 
disease populations (Costa et al., 2015). In the U.S., medication non-adherence has been 
responsible for 125,000 deaths and is estimated to well exceed $100 billion in healthcare 
expenditures annually (Viswanathan et al., 2012). The average cost per successful 
pregnancy and birth for women who undergo cycle-based infertility treatment is over 
$48,000 (Katz et al., 2011). Non-adherence to fertility medication is usually not life-
threatening, although fertility quality of life has been a concern (Boivin, Takefman, & 
Braverman, 2011). Women’s perceptions about their infertility treatment experience has 
been associated with quality of life (Aarts et al., 2012). The relationship between fertility 
quality of life and medication adherence behaviors has not been established.  
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Strengths and Limitations 
The unprecedented nature of the findings in this systematic review serves as a major 
strength by offering evidence that oral medication adherence, used as first-line fertility 
therapy, could be more problematic than previously assumed by clinicians and researchers. 
Two of the three studies used randomization into group assignment, which minimizes study 
bias and strengthens findings. Nonetheless, several limitations exist that must be scrutinized. 
First, studies not published in the English language were excluded, and studies published in 
other languages could have altered the results. Second, this review included a very small 
sample size, and most study subjects were a subpopulation of infertile women with PCOS, 
limiting generalizability of findings. Only three studies were included for this review after 
two studies were excluded secondary to suspicion of same sample groupings. Third, the 
studies were focused only on oral medications during first-line therapy and did not include 
injection medications nor medication adherence during IUI and IVF treatment cycles. 
Fourth, one study examined medication adherence retrospectively. Although retrospective 
studies help establish cause and effect relationships (contributory factors), interpretation of 
study findings is limited, particularly when both selection bias and recall bias are present. 
Fifth, different tools were used to measure medication adherence, which could potentially 
confound results and hinder study inferences.  
Implications from the Findings 
As initiatives are in motion to broaden access for infertility services, understanding 
medication-taking patterns will be important. Reproductive healthcare providers should 
reinforce the importance of following medication regimens. The validation of medication 
adherence in research trials involving assisted reproductive therapies will better inform, 
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cultivate, and perpetuate stronger innovative discoveries in reproduction science to 
strengthen clinical practice.  
Recommendations for Future Research 
 Future investigations are needed exploring women’s medication adherence patterns 
during IUI and IVF cycles. Insight on how healthcare delivery of infertility services (e.g., 
degree of patient-centeredness, healthcare team communication, availability of third-party 
reimbursement) impacts medication taking could reinforce continuity of care and 
consequently, medication adherence. The impact of infertility insurance coverage on 
medication adherence rates deserves further attention as healthcare costs continue to 
skyrocket. Determination of whether adherence rates differ by regions of mandated 
infertility insurance coverage would also be beneficial. The relationship between motivation 
to conceive and likelihood of adherence will be important if theory driven interventions are 
deemed necessary. Moreover, investigating how quality of life and environmental factors 
impact medication adherence will be important particularly when family support and 
treatment demands (e.g., psychological stress and anxiety, time off work for appointments, 
treatment costs) could affect decisions regarding continuation of services. Lastly, 
standardization of medication adherence tools is needed in future infertility research. 
Conclusion 
The study findings from this review confirm that fertility medication adherence 
research remains scarce. Additional research is timely and compelling. The state of the 
science on fertility medications is still underdeveloped when compared to the general 
medication adherence research. Aligning medication-taking behaviors with reproductive 
outcomes (i.e., canceled cycles, clinical pregnancies, live birthrates) during IUI and IVF 
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cycles in future studies will help determine if tailored interventions are indicated. Oral 
medication adherence rates are suboptimal when used alone as first-line therapy. Further 
investigation of medication-taking behaviors is warranted in future research trials involving 
injection medications and COH cycles associated with IUI and IVF cycles to strengthen 
clinical practice. Greater exploration into such unchartered territory will answer the call of 
scientific inquiry through fostering innovation and versatility to advance human 
reproduction science.  
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CHAPTER 3 
THEORETICAL FRAMEWORK AND METHODOLOGY 
 Barriers of and Facilitators to Infertility Medication Adherence Study 
(B-NFORMED): A Mixed Methods Study was supported by theory. This study design was a 
convergent mixed methods design in which quantitative and qualitative data assessing 
barriers to and facilitators of infertility MA were collected simultaneously and correlated 
with 1-2 consecutive months of electronically monitored infertility MA behaviors. A mixed 
methods design was used to gain deeper insight concerning this matter and maximize 
strengths of both quantitative and qualitative designs.  
Theoretical Framework 
 In a recent systematic review (Mahoney et al., 2019), it was found that no supporting 
theoretical framework was used to guide studies that investigated women’s medication-
taking behaviors while undergoing infertility treatment. The theoretical framework guiding 
the B-NFORMED study was the Reasoned Action Model (Fishbein & Ajzen, 2010).  
Fishbein and Ajzen’s Reasoned Action Model 
 Fishbein and Ajzen’s Reasoned Action Model (2010), the most current theoretical 
formulation for predicting human social behavior, postulates that intention determines the 
likelihood of behavior performance. For more than 50 years, Drs. M. Fishbein and I. Ajzen 
have worked jointly and individually to refine their approach to predicting and changing 
behavior (Ajzen, 1985, 1988, 1991; Ajzen & Fishbein, 1969, 1970, 1977, 1980, 2000, 2004; 
Fishbein, 1963, 2003; Fishbein & Ajzen, 1974, 1975, 2005, 2010).  
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Evolution of the Reasoned Action Model 
 Fishbein’s (1963) early expectancy-value model purported that behavioral beliefs 
about the likely outcome of performing a certain behavior directly influenced one’s attitude 
about that behavior. Ajzen and Fishbein (1980) subsequently collaborated to explore 
attitudes, behaviors, and intentions, later formulating a theory known as the Theory of 
Reasoned Action (TRA). The TRA addressed the normative construct—acknowledging that 
normative beliefs were weighted by motivation to adhere to a behavior change— that was 
lacking in prior work (Ajzen & Fishbein, 1969, 1970, 1977, 1980; Fishbein & Ajzen, 1974, 
1975).  
 Additionally, the TRA incorporated background factors that include demographic 
variables (e.g., age, gender, education, race) and individual differences (e.g., personality, 
mood, emotions) that were thought to indirectly influence one’s behavioral beliefs and 
normative beliefs toward performing a certain behavior. Further, Ajzen (1985, 1988) 
introduced an additional construct, perceived behavioral control. In congruence with 
behavioral beliefs and normative beliefs within the TRA, control beliefs were proposed as a 
function of people’s perception of their control over performing a behavior. This extension 
to the existing theory became known as the Theory of Planned Behavior (TPB) (Ajzen, 
1988, 1991).  
 Meanwhile, responding to a national initiative to unify variables among major 
theories that guided HIV prevention research, Fishbein (2000) modified the theory by 
surmising the Integrative Model that further incorporated attitudes, perceived norms, and 
self-efficacy as functions of underlying beliefs about performing a specified behavior. 
Although both theorists continued to work independently, Fishbein’s Integrative Model 
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(2000) shared similarities to Ajzen’s (1991) TPB. Thus over time, the two theorists reunited 
to resolve differences between their models that resulted in the most current framework, the 
Reasoned Action Model (Fishbein & Ajzen, 2010).  
Present Reasoned Action Model  
 Fishbein and Ajzen (2010) contended that people’s beliefs about a behavior is 
assumed to regulate their intention to engage in that behavior. Intentions are indicative of 
one’s willingness or readiness to implement a behavior (Fishbein & Ajzen, 2010). Beliefs 
about respective behaviors are derived from a host of background factors such as personal 
experiences, personality, income, religion, age, race/ethnicity, education, and family 
dynamics. Background differences between individuals are considered to influence how 
information is recalled and interpreted, which impacts beliefs (Fishbein & Capella, 2006). 
These beliefs that influence one’s decision whether to perform a certain behavior have been 
categorized into three determinants of intention—behavioral beliefs, normative beliefs, and 
control beliefs (Fishbein & Ajzen, 2010; Fishbein & Capella, 2006). 
 Behavioral beliefs are assumed to regulate an individual’s attitude toward 
performing a behavior. As such, one’s attitude with respect to performing a behavior will be 
more or less favorable based on the extent to which performance of the behavior is 
perceived as positive versus negative. Normative beliefs are based on the extent to which 
important people in one’s life would approve or disapprove of a behavior being performed. 
Thus, if a majority of important people are believed to approve of the behavior or actually 
performs the behavior themselves, the more likely the individual will perceive societal 
pressure to perform the behavior (Fishbein & Ajzen, 2010). Figure 3.1 shows a schematic 
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representation of the Reasoned Action Model. The Reasoned Action Model is also displayed 
in Appendix A. 
 
 
Figure 3.1. Fishbein and Ajzen’s Reasoned Action Model (Fishbein & Ajzen, 2010) 
 
 The B-NFORMED study concentrated on (a) women’s background factors and 
varying personal experiences with infertility treatment that could influence their beliefs 
about medication-taking, (b) behavioral beliefs that influence women’s attitudes toward 
infertility medication-taking, (c) normative beliefs that originate from women’s perceptions 
of social pressure from important persons that approve or disapprove of their decision to 
undergo infertility treatment, and (d) control beliefs (perceived barriers and facilitators) as 
determinants of behavioral intention that can impact women’s likelihood of performing the 
behavior of interest, infertility MA. Control beliefs are perceived personal and 
environmental factors that inhibit or help the likelihood of performing a behavior (Fishbein 
& Ajzen, 2010). These beliefs determine one’s self-efficacy or perceived behavioral 
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control—one’s perception of the extent of barriers and facilitators that are present (Fishbein 
& Ajzen, 2010).  
 Perceived behavioral control moderates the effects of intentions on behavior. If more 
facilitators are perceived than barriers, one’s level of perceived behavior control will be 
high. The stronger the intention to perform a behavior, the greater likelihood the behavior 
will be performed. Insufficient abilities, skills, and environmental constraints could 
realistically prevent an individual from acting on intention to perform, which is known as 
actual control. Collectively, a person’s attitude about executing the behavior, perception of 
social pressure to perform a behavior, and perception of barriers to and facilitators of 
accomplishing a behavior leads to readiness to perform that behavior (Fishbein & Ajzen, 
2010).  
Methodology 
 The following is a description of the methodology used in the research design and 
participant recruitment. Setting for recruitment of participants, data collection methods, 
instrument selection, and psychometric properties are discussed. Lastly, study procedures 
and data management are presented. 
Research Design 
 The Primary Investigator (PI) conducted a correlational, convergent mixed methods 
design in which quantitative and qualitative data were collected simultaneously and 
correlated with one to two consecutive months of electronically monitored infertility MA 
behaviors. A mixed methods approach was most suited to understand the complexities 
surrounding medication-taking patterns of women undergoing infertility treatment by 
generating richer data than either a quantitative or qualitative method alone (Johnson, 
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Onwuegbuzie, & Turner, 2007). Questionnaire data were collected at baseline on the study 
variables, MA barriers and background factors. Interview data were generated at baseline on 
the study variables, MA facilitators and personal experiences with infertility treatment. MA 
behaviors were documented by one to two months (one to two fertility treatment cycles) of 
electronic monitoring using MEMS®. MA barriers were measured using the Adherence 
Starts with Knowledge (ASK-20) Adherence Barrier Survey (Hahn et al., 2008). 
Background factors were assessed using a demographics questionnaire. MA facilitators and 
personal experiences with infertility treatment were measured by the PI via a structured 
interview. MA was measured using MEMS®. 
Participants  
 The study population were women undergoing infertility treatment. The RRC patient 
volume was sufficient to recruit a convenience sample of 30 participants in the study 
timeframe. A recent study (Atsuta et al., 2017) revealed a correlation (r) of -0.51 between 
mean ASK-20 Adherence Barrier Survey total scores and MA scores, which represents a 
large effect (r²= .26) based on Cohen’s (1988) criteria for evaluating effect size measured by 
r².Thus a power analysis using the G*Power 3 computer program (Faul, Erdfelder, Lang, & 
Buchner, 2007) indicated that a total sample size of 27 was needed to a detect a minimum 
correlation of 0.51 with 80% power using a t-test for correlation with alpha at .05. Figure 3.2 
describes recruitment details.  
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Figure 3.2. Participant Recruitment 
 Inclusion criteria for women receiving infertility treatment were: (1) age 20-44 years; 
(2) currently prescribed at least one oral daily dosed infertility medication under the care of 
a Reproductive Resource Center infertility provider; (3) ability to open an electronic 
monitoring cap with bottle as assessed by PI; (4) willingness to the use the electronic 
monitoring cap with bottle to store infertility medications; (5) self-administers infertility 
medication; (6) ability to read and write English; and (7) has a telephone or has access to a 
telephone. Women undergoing infertility diagnostic testing who have not begun taking 
infertility medications were excluded. Although ages of 15 to 44 years are considered 
female reproductive years, women younger than 20 years are not considered a population 
who seeks infertility services (Chandra et al., 2013). Women beyond the age of 44 are 
considered to have a significantly diminished reproductive potential (ASRM, 2012a).  
 A total targeted sample size of 30 participants were selected based on the power 
analysis and additional data generated from prior studies that assessed barriers of and 
 
Available at RRC: 300 
 
67% anticipated to meet criteria: 200  
 
65 approached to join the study  
 
75% agree to join the study: 49 
 
90% anticipated to qualify: 44 
 
25% treatment dropout rate: 33  
 
 90% anticipated to the complete study  
 
End of study: 30 
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facilitators to MA in other patient populations using qualitative or mixed methods research 
designs (Castro, Santiago, Jiménez, Dávila-Vargas, Rosal, 2015; Claes, Decorte, 
Levtchenko, Knops, & Dobbels, 2014; Curioso, Kepka, Cabello, Segura, & Kurth, 2010; 
Ho, Jacob, & Tangiisuran, 2017). Unfortunately, similar studies are lacking in women 
undergoing infertility treatment. An adherence rate score of 1.00 was selected to divide the 
adherers from the non-adherers because no prior research has established infertility MA 
scores of less than 1.00 to achieve optimal reproductive outcomes. Moreover, infertility 
treatment practice guidelines have not documented adherence scores of less than 1.00 to be 
acceptable for establishing treatment effectiveness within the clinic setting (Gianaroli et al., 
2012; Practice Committee of the American Society for Reproductive Medicine, 2006). More 
specifically, the effect of missed medication doses (dose-dependent efficacy) on pregnancy 
rates and surrogate measures of infertility treatment effectiveness (e.g., follicular 
development, changes in hormone levels, cervical mucus quality, and ovulation) has not 
been established. 
 Recruitment. During the clinic visit, infertility healthcare providers and nurses 
informed patients who met the inclusion criteria about the study and asked if they were 
willing to meet with the PI on the day of their visit. Infertility provider referral has been 
shown to be the most effective recruitment strategy during infertility research trials (Usadi et 
al., 2015). Prospective participants who agreed to meet with the PI were escorted to a private 
room located at the clinic where the PI greeted them and informed them further about the 
study. Those who opted to be enrolled in the study signed an IRB-approved consent form.  
 Minority recruitment. In comparison to United States population demographics, 
African American women and women of Hispanic ethnicity are underrepresented in the 
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population of women seeking infertility treatment services. This disparity has been 
attributed to a combination of economic, cultural, and social background factors (Daar et al., 
2015; Green, Robins, Scheiber, Awadalla, & Thomas, 2001). White women represent 85.2% 
of clients seeking infertility treatment services, African-American women 10.2%, and other 
minorities 4.4% (Jain, 2006). In an effort to include minority women in this study, the 
infertility healthcare providers and nurses identified potential participants for recruitment. 
Also, the PI is an African-American female, which was assumed to enhance participant 
comfort level with study participation. Minority researchers possess unique insight from 
their own experiences and can anticipate important issues concerning cultural sensitivity 
matters (Vermund et al., 2018). 
Setting 
 The participant population of interest, women receiving infertility treatment, were 
recruited from Reproductive Resource Center (RRC). Access was granted to the PI to 
conduct this study at RRC. A letter of support (see Appendix B) was provided by the owner, 
who is also the Medical Director. RRC is a reproductive endocrinology and infertility 
practice located in Overland Park, Kansas, which provides infertility services to women 
residing in urban, suburban, and rural regions of Kansas, Missouri, and neighboring states. 
This clinic serves approximately 300 women monthly (80% White, 10% Black/African 
American, 6% Hispanic/Latino, and 4% American Indian/Alaska Native, Asian, Native 
Hawaiian/Pacific Islander) who could be screened for enrollment in this study. The 
racial/ethnic demographics of women seen at RRC are consistent with the general 
population of women who undergo infertility treatment at reproductive endocrinology and 
infertility centers nationally (Daar et al., 2015; Green et al., 2001; Jain, 2006). The ages of 
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women seen at RRC ranges from 20 to 49 years. RRC provides a full scope of infertility 
treatment including oral and injection medications, intrauterine insemination, and in-vitro 
fertilization. The RRC healthcare team includes two reproductive endocrinologists, six nurse 
practitioners, two registered nurses, and one medical assistant.  
Conceptual Definitions 
 Background Factors. Background factors were conceptually defined as intrinsic and 
extrinsic factors that can influence women’s beliefs about infertility medication-taking, such 
as age, race/ethnicity, education, and income. 
 Medication Adherence Barriers. Barriers to MA were conceptually defined as 
challenges and obstacles to adherence to infertility medication regimen. 
 Medication Adherence Facilitators. Facilitators of MA were conceptually defined as 
factors that promote adherence to infertility medication regimen. 
  Personal Experiences with Infertility Treatment. Personal experiences with 
infertility treatment were conceptually defined as women’s thoughts and feelings regarding 
the personal impact of receiving infertility treatment.  
  Medication Adherence. MA was conceptually defined as the percent to which 
women’s oral infertility medication-taking behaviors, with respect to taking, timing and 
dosing, are consistent with the infertility health care provider’s prescription.  
Instruments 
 Background Factors. Background factors were evaluated using a Demographic 
Questionnaire developed by the PI (see Appendix C) that assesses age, race/ethnicity, 
marital status, level of education, income, list of current infertility medications and dosing 
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schedules, and source of payment for infertility services (self-pay, partial out-of-pocket, 
fully insured). 
 Medication Adherence Barriers. MA barriers were measured using the ASK-20 
Adherence Barrier Survey (Hahn et al., 2008) (see Appendix D). This 20-item self-
administered survey takes approximately five minutes to complete. It addresses barriers to 
adherence based on knowledge, attitudes, social support, lifestyle, side effects, financial 
demands, relationship with healthcare provider, and overall medication taking. The ASK-20 
Adherence Barrier Survey has a possible scoring range of 20 to 100. A five-point Likert type 
scale is used with a degree of agreement anchor response format of Strongly Agree, Agree, 
Neutral, Disagree, and Strongly Disagree for each item. Higher scores represent a greater 
number of barriers to MA. The ASK-20 Adherence Barrier Survey has a good internal 
consistency of .85 and a test-retest reliability of .80 (Hahn et al., 2008; Martza et al., 2008). 
Criterion validity was established with significant validity coefficient correlations of .20 to 
.61 between the ASK-20 Adherence Barrier Survey and several self-reported MA measures 
(Hahn et al., 2008; Martza et al., 2008). A letter of permission to use this survey is provided 
in the Appendix E. 
 Medication Adherence Facilitators. MA facilitators and personal experiences with 
infertility treatment were measured by the PI by conducting a structured interview using an 
Interview Guide (see Appendix F). 
 Personal Experiences of Infertility Treatment. Personal experiences with infertility 
treatment were measured by the PI by conducting a structured interview using an Interview 
Guide (see Appendix F).  
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 Medication Adherence. MA was based on: (a) taking adherence—the percentage of 
prescribed doses taken, (b) dosing adherence—the percentage of days with correct dosing, 
and (c) timing adherence—the number of doses taken at 24 ± 6 hours (inter-dose intervals 
within 25% of the prescribed interval ) for a once-daily regimen. MA was measured using 
the MEMS® (see Appendix G). A MEMS® diary was used to help validate the MEMS™ 
data (see Appendix H). MA data were retrieved from the MEMS® caps. The MEMS®8 
Track CAP with liquid-crystal display (LCD) is a medication bottle cap containing 
microelectronics that record each cap removal and the time of the removal. Each MEMS® 
cap contains a battery and microelectronic circuitry that record a date and time with each cap 
removal from the bottle. The device has a 36-month battery life. Perfect accuracy on 
detection of time and date of cap removal has been observed with MEMS® usage 
(De Bleser et al., 2010). When the PI retrieved the caps from the participants, data were sent 
wirelessly to the password-protected medAmigo database, a platform that allows the PI to 
visualize participants’ adherence data. A cumulative record of cap openings, beginning the 
day after the participant was instructed on use of the cap, was compiled for each participant. 
This report contained a listing and graphic of individual bottle openings and closings, the 
duration of opening, and the hours elapsed since the previous opening. Since accidental cap 
openings could occur, the MEMS® diary was used to document these events.  
 The MEMS® cap data were corrected by the PI using the MEMS® diary data. After 
any corrections were made, each cap removal was presumed to represent the patient 
ingesting one dose of the prescribed infertility medication. The MEMS® is considered 
accurate because it records the time and date of actual removal of the bottle cap 
(Denhaerynck et al., 2008). Limitations have been identified with the use of MEMS®, 
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including the inability to determine if the medication was consumed, failure to open the cap 
when the participant took out more than one dose of medication ahead of time to avoid 
carrying the MEMS® bottle around while away from home, and occurrences of bottle 
openings by mistake (Denhaerynck et al., 2008; Métry & Meyer, 1999; Russell et al., 2006). 
In effort to overcome such potential limitations, the PI reinforced the importance of 
documenting in the MEMS® diary if such incidences occurred. A summary of data 
collection approaches is provided in Table 3.1. 
Table 3.1 
Summary of Instruments 
Variable Measure Psychometrics 
(reliability and 
validity) 
Administration 
Time Points 
Background Factors Demographic 
Questionnaire 
Not applicable Baseline 
Medication 
Adherence Barriers 
ASK-20 
Adherence Barrier 
Survey 
Internal consistency 
reliability 
(Cronbach’s alpha) = 
.85 
Test-retest reliability 
=.80 
Criterion validity = 
.20 to .61 
Baseline 
Medication 
Adherence 
Facilitators 
PI conducting 
structured 
interviews 
Not applicable Baseline 
Personal 
Experiences with 
Infertility Treatment 
PI conducting 
structured 
interviews 
Not applicable Baseline 
Medication 
Adherence 
MEMS® and 
MEMS® diary 
Microelectronic 
circuitry yields 
100% accuracy 
detection on time 
and date of cap 
removal. 3-year 
battery life. 
2 Months/2 
Infertility 
Treatment Cycles 
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Procedure 
 The research protocol was approved by the Institutional Review Board (IRB) at the 
University of Missouri-Kansas City (UMKC). Dr. Celeste Brabec, Owner and Medical 
Director of RRC, deferred IRB review to UMKC (see Appendix I). The PI met with RRC 
clinic staff during a weekly staff meeting and provided study details and laminated 
inclusion/exclusion pocket cards for their convenience in identifying prospective 
participants. During the clinic visit, the infertility healthcare providers and nurses informed 
patients who meet the inclusion criteria about the study and asked if they were willing to 
meet with the PI on the day of their visit. Infertility provider referral has been shown to be 
the most effective recruitment strategy during infertility research trials (Usadi et al., 2015). 
However, the PI made the final determination of inclusion/exclusion for each individual 
referred to her. Prospective participants who agreed to meet with the PI were escorted to a 
private room located at the clinic, where the PI greeted and introduced herself to the 
participant and provided verbal explanation of the study’s purpose, procedures, potential 
benefits and risks, possible scientific gains, and participation honoraria.  
 The PI reviewed the participants’ rights and emphasized the voluntary nature of 
participation in the study. The potential participant was informed that participation in the 
study could be terminated at any point, and that participation or non-participation would 
have no influence on her care at RRC. The PI answered any questions that the individual had 
about the study. If the individual agreed to be in the study, the PI reviewed the consent and 
obtain informed consent. Individuals who declined to be enrolled in the full study would 
have been given an option to consent to provide their demographic information only (i.e., 
age, race/ethnicity, marital status, level of education, income, and source of payment for 
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infertility services (self-pay, partial out-of-pocket, fully insured). This would have allowed 
the PI to assess and compare the demographics of those who consented to be enrolled in the 
study and those who declined to be enrolled in the study.  
 The PI collected the telephone numbers of participants. If the consented participant 
was not able to complete baseline visit activities on the day of this clinic visit, the PI offered 
the participant the option of completing these activities during a scheduled visit at a location 
of choice or at the next scheduled clinic visit. If the participant preferred a visit at a location 
of choice, the PI scheduled that visit and obtained the location address in addition to the 
telephone number that was collected. If the participant opted to complete the initial study 
activities at the next clinic appointment, the PI obtained the appointment date and time from 
the participant and confirmed this appointment with a member of the front office clinic staff. 
On clinic days when the PI was not present, yet infertility providers identified patients who 
met study criteria and expressed interest in being enrolled in the study, the providers and 
nurses maintained these names and telephone numbers for the PI. The PI later called these 
women and offered them the option of a scheduled visit at a location of choice or seeing 
them at their next scheduled clinic visit, where informed consent was obtained.  
The PI demonstrated skills for establishing and maintaining rapport with participants 
throughout the study. The baseline visit (see Steps 1 to 4, below) lasted approximately 35 to 
40 minutes. The remaining one to two months of the study consisted of infertility 
medication-taking monitoring with MEMS®, MEMS® diary, and one to two follow-up 
telephone calls (see Step 5). Study activities are described below: 
• Step 1: (Total time 5 minutes). The PI administered a Demographic 
Questionnaire. 
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• Step 2: (Total time 5 minutes). The PI administered the ASK-20 Adherence 
Barrier Survey. 
• Step 3: (Total time 10 to 15 minutes). The PI conducted the structured interview. 
• Step 4: (Total time 15 minutes). The PI trained the participant on how to use the 
MEMS® and MEMS® diary for the two-month electronic monitoring phase. 
The participant used the MEMS® cap with one randomly selected infertility 
medication that was to be taken once daily. Only one prescribed infertility 
medication was monitored because prior research has shown that monitoring a 
second medication does not provide additional MA information (Haynes et al., 
2006). When applicable, the PI numbered all the once-daily administered 
infertility medications listed on the Demographics Questionnaire. The PI entered 
that number into a random numbers generator and had the participant monitor 
the infertility medication that was randomly selected. The PI instructed the 
participant to (1) place one of the infertility medications into the MEMS®, 
bottle, (2) keep the medication in the bottle and not take it from any other 
containers, and (3) place all new refills of the medication into the bottle. The 
participant was instructed on the use of the MEMS® diary to document any 
accidental cap openings, openings when no medication was ingested (e.g., when 
refilling MEMS® bottle), and early openings when a medication was removed 
early to take later, but on time. The participant was given specific examples of 
when the diary should and should not be used. The participant was then trained 
to store the diary with the MEMS® bottle. Training continued until the 
participant achieved 100% accuracy using the MEMS® diary with the four 
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MEMS® diary test scenarios (accidental opening, early opening, opened but no 
medication administered, diary storage). The PI gave the participant an 
addressed envelope with prepaid postage to mail the MEMS® cap device to the 
PI at study completion. A $25.00 gift card was given to the participant as an 
honorarium. 
• Step 5: (Total time: one to two months). The PI assessed infertility medication 
taking behaviors during one to two months of electronic monitoring. This two-
month timeframe was selected to avoid the Hawthorne effect, because a 
monitoring period under one month has been shown in prior studies to be less 
reliable (De Bleser et al., 2011). However, in the current study, the first month 
of MEMS® data was not discarded because infertility treatment often requires 
intervals of stopping and restarting medications cyclically; thus the likelihood of 
the Hawthorne effect would not be weakened over time. The participant used the 
MEMS® and MEMS® diary as described in Step 4 for a duration of one to two 
treatment cycles. If the participant became pregnant prior to study completion, 
the participant was instructed to notify the PI and to discontinue the MEMS® 
and MEMS® diary and mail them to the PI as described below. The PI 
conducted one-month and two-month follow-up telephone calls (lasting 
approximately five minutes, see Appendix J) to make sure the participant was 
using the MEMS® correctly after the training and to assess if there were any 
questions or concerns about the MEMS® diary. After one to two months, the 
participant mailed the MEMS® diary and MEMS® cap device to the PI so that 
she could retrieve data through the MEMS® software program. Upon receiving 
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the MEMS™ cap device and diary, the PI mailed the participant a second $25.00 
gift card as an honorarium. 
Risk Reduction 
 IRB approval (Protocol Number: 18-262) was obtained from UMKC. Dr. Celeste 
Brabec, Owner and Medical Director of RRC, deferred IRB review to UMKC (see 
Appendix I). Once the study was initiated, participants’ confidentiality was maintained using 
the following techniques: (1) the PI was responsible for all data management, (2) each 
participant was given a unique study identification code to enable data source merging (e.g., 
demographics, MEMS® data), (3) the unique study identification codes were stored in a 
locked separate file, (4) all data were entered and stored in the password-protected REDCap 
data system, (5) all participant names and other identifiers were removed from the data upon 
assignment of a study identification code. 
 The risk of physical harm was minimal for participants in this protocol. The study 
procedures were designed to not interfere with routine medical care; thus there was little 
potential for adverse events directly related to study procedures. The study procedures were 
performed parallel to the infertility treatment care plan; therefore, study participation did not 
introduce direct medical or physical risk to the patient. To further reduce possible physical 
risk, the PI was trained regarding situations when she should refer the participant to the 
infertility clinic, forward information to the infertility clinic, or contact the infertility care 
team directly. The PI is also a DNP-prepared infertility nurse practitioner. The PI was aware 
that the data collection process could generate emotional responses during the interviews. If 
this had occurred, the PI would have provided the participant time to express significant 
emotion, acknowledge the importance of this to the wellbeing of the participant, and refer 
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her to a licensed counselor who specializes in struggles associated with infertility 
(Complementary Care Group, 2012). 
 Adverse events related to using MEMS® were unlikely. However, the PI asked 
participants during each telephone encounter if they experienced any MEMS®-related 
problems with taking their medications. Any perceived problems would have been 
documented exactly as participants presented them. The PI would have probed with follow-
up questions. Any significant events would have been shared immediately with the infertility 
practice clinic manager. Any participant who appeared to have experienced an adverse event 
related to using the MEMS® would have been immediately withdrawn from the study and 
IRB would have been notified.  
Data Management 
 All study data were maintained in the password-protected Research Electronic Data 
Capture ([REDCap], 2006) data system. The electronic medication monitoring data, 
identified only by the participant’s unique code number, was encrypted and sent wirelessly 
to the MEMS® database. Only aggregate data were reported. Data analysis was conducted 
by the PI using SPSS version 24 (IBM Knowledge Center, n.d.) and supervised by Dr. A. 
Cheng, the University of Missouri-Kansas City biostatistician. The PI took all measures to 
ensure all data points were collected; however if missing data were more than 10% in this 
study, multiple imputation technique would have been employed to guarantee the best 
statistical analysis results.  
Data Analysis  
 For demographic data, percentages, means, ranges, and standard deviations are 
reported.  
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Hypothesis 1. Women with a greater number of perceived barriers will demonstrate 
lower infertility MA scores than women with a lesser number of perceived barriers. 
Analysis plan. The assumption of normality was not met for the distribution of MA 
scores based on the small sample size (n=18) that used MEMS®. Thus Spearman’s rho 
correlation coefficient was computed to assess the relationship between perceived barriers 
measured with the ASK-20 Adherence Barrier Survey (independent variable) and MA 
scores (dependent variable) measured with one to two months of MEMS® data at a 
significance level of .05. 
Hypothesis 2. Women with a greater number of perceived facilitators will 
demonstrate higher MA scores than women with a lesser number of perceived facilitators.  
Analysis plan. The interviews were audiotaped, transcribed, and data coded using a 
thematic approach. Response codes with functionally equivalent meaning were assigned to 
thematic categories. Those with overlapping themes were merged into one category. 
Thematic categories were transformed into quantitative counts (encoded to thematic 
variables). The assumption of normality was not met for the distribution of MA scores based 
on the small sample size (n=18) that used MEMS®. The Spearman’s rho correlation 
coefficient was computed to assess the relationship between the number of thematic 
(independent) variables, representing perceived facilitators, and measured MA scores 
(dependent variable) measured with one to two months of MEMS® data at a significance 
level of .05.  
Hypothesis 3. Differences will exist among perceived barriers and facilitators 
between women who were adherent and women who were non-adherent. 
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Analysis plan. The assumption of normality was not met for the distribution of MA 
scores based on the small sample size (n=18) that used MEMS®. The Mann-Whitney U test 
or the Chi-Square test was used to compare group differences in perceived barriers measured 
by the ASK-20 Adherence Barrier Survey and thematic perceived facilitator variables 
between two groups—women who were adherent and women who were non-adherent—at a 
significance level of .05. Degree of adherence was dichotomized as the following: adherent 
group=MEMS® adherence score of 100% and non-adherent group=MEMS® adherence 
score of less than 100%. 
Hypothesis 4. Differences will exist in women’s personal experiences with infertility 
treatment based on women’s age, race/ethnicity, level of education, income, and infertility 
insurance status.  
Analysis plan. The interviews were audiotaped, transcribed, and data coded using a 
thematic approach. Response codes with functionally equivalent meaning were assigned to 
thematic categories. Those with overlapping themes were merged into one category. The 
Chi-Square Test was used to determine if there were statistically significant differences 
between quantified thematic categories (personal experiences) and five categorical 
(nominal) variables (age, race/ethnicity, level of education, income, and insurance status) at 
a significance level of .05. 
Hypothesis 5. Differences will exist between adherent and non-adherent women by 
age, race/ethnicity, level of education, income, and infertility insurance status.  
Analysis plan. Level of adherence was dichotomized as the following: adherent 
group=MEMS® adherence score of 100% and non-adherent group=MEMS® adherence 
score of less than 100%. The assumption of normality was not met for the distribution of 
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MA scores based on the small sample size. (n=18) that used MEMS®. The Chi-Square test 
was used to determine if there were statistically significant differences between the two 
dichotomized variables (adherent versus non-adherent) and five categorical (nominal) 
variables (age, race/ethnicity, level of education, income, and insurance status) at a 
significance level of .05. 
Exploratory hypothesis. Differences will exist between women who were adherent 
and women who were non-adherent based on women’s personal experiences with 
undergoing infertility treatment. 
Analysis plan. Level of adherence was dichotomized as the following: adherent 
group=MEMS® adherence score of 100% and non-adherent group=MEMS® adherence 
score of less than 100%. The assumption of normality was not met for the distribution of 
MA scores based on the small sample size. The Chi-Square test was used to determine if 
there were statistically significant differences between the two dichotomized variables 
(adherent versus non-adherent) and categorical (nominal) thematic personal experiences 
with undergoing infertility treatment at a significance level of .05. 
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CHAPTER 4 
RESULTS 
 Chapter 4 is a report of findings related to the research questions. This chapter is 
organized by recruitment and enrollment, participant characteristics, the primary research 
question and working hypotheses, the secondary research question and secondary 
hypotheses, and the exploratory research question and exploratory hypothesis. 
Recruitment and Enrollment 
 Participants were recruited from October 2018 to December 2018 from Reproductive 
Resource Center. Forty-seven participants were invited to take part in the study but 17 
declined this invitation, which yielded 30 participants enrolled in the study and a 64% 
consent rate. Demographic data were not obtained on those who declined participation 
because consent to obtain demographic data would have occurred when the PI spoke with 
these individuals. However, these 17 individuals informed the infertility clinic providers that 
they did not want the PI to contact them. Reasons they declined to take part in the study and 
declined PI contact were not obtained.  
 All 30 consented participants completed the demographics questionnaire, MA 
barriers questionnaire, and the structured interviews. Forty percent (n=12) of the women did 
not use MEMS® because four became pregnant, four decided to pursue IVF, three decided 
to discontinue infertility treatment, and one decided to pursue embryo donation. Of the 18 
(60%) participants who used MEMS® during infertility treatment cycles, 33.3% (n=6) used 
MEMS® for two treatment cycles. Sixty-seven percent (n=12) of the women used MEMS® 
for one treatment cycle because three decided to pursue IVF, three decided to suspend 
treatment indefinitely, three did not follow MEMS® protocol and returned the MEMS® 
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caps prior to the second treatment cycle, one decided to discontinue infertility treatment,  
one became pregnant, and one had provider-deferred treatment plan secondary to 
experiencing menstrual problems. Figure 4.1. depicts a flow diagram using STROBE 
Statement Guidelines. 
Patient Characteristics 
 The mean age of all participants was 31.3 (SD= 3.93) years with a range of 24 to 39. 
Baseline sample demographic data (background factors) are found in Tables 4.1 and 4.2. 
Participants were predominately White 83.3% (25/30), Non-Hispanic 90% (27/30), married 
100% (30/30), aged 25 to 30 years 43.3% (13/30), resided in a suburban community 83.3% 
(25/30), had a $75,000 to $99,999 household income 30% (9/30), held a Bachelor’s degree 
50% (15/30), had partial out-of-pocket payment responsibility for infertility treatment 
services 56.7% (17/30), had no prior child 80% (24/30), and experienced two to three prior 
unsuccessful treatment cycles 46.7% (14/30).  
The mean age of the 18 (60%) participants who used the MEMS® was 31.8 (SD= 
3.65) years with a range of 24 to 39. Baseline sample demographic data (background 
factors) are found in Tables 4.1 and 4.2. Participants were predominantly White 83.3% 
(15/18), Non-Hispanic 94.4% (17/18), married 100% (18/18), aged 31 to 35 years 44.7% 
(8/18), resided in a suburban community 88.9% (16/18), had a $75,000 to $99,999 
household income 27.8% (5/18), held a Bachelor’s degree 61.1% (11/18), had partial out-of-
pocket payment responsibility for infertility treatment services 50% (9/18), had no prior 
child 76.8% (14/18), and either experienced zero to one 38.9% (7/18) or two to three prior 
unsuccessful treatment cycles 38.9% (7/18).  
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Figure 4.1. Flow Diagram using STROBE Statement Guidelines 
MEMS®= Medication Event Monitoring System®  
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Table 4.1 
Sample Demographics 
 
Background Factors Total Sample 
n (%) 
Participants who used 
MEMS® 
n (%) 
Race   
Non-Hispanic White 25 (83.3) 15 (83.3) 
Hispanic or Mexican American  2 (6.7)  1 (5.6) 
Asian  1 (3.3)  1 (5.6) 
Black or African-American  1 (3.3)  1 (5.6) 
American Indian or Alaskan 
Native 
 1 (3.3)  0  
Ethnicity   
Non-Hispanic or Latino 27 (90) 17 (94.4) 
Hispanic or Latino  3 (10)  1 (5.6) 
Marital Status   
Married 30 (100) 18 (100) 
Age Range   
20-24 years  1 (3.3)  1 (5.6) 
25-30 years 13 (43.3)  7 (38.9) 
31-35 years 12 (40)  8 (44.4) 
36-40 years  4 (13.3)  2 (11.1) 
Residence   
Suburban 25 (83.3) 16 (88.9) 
Rural  3 (10)  1 (5.6) 
Urban  2 (6.7)  1 (5.3) 
Note. MEMS® = Medication Event Monitoring System. Total n=30.  
Participants who used MEMS® n= 18 
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Table 4.2 
Sample Demographics 
 
Background Factors Total Sample 
n (%) 
Participants who 
used MEMS® 
n (%) 
Household Income   
$50,000-$74,999   4 (13.3)   3 (16.7) 
$75,000-$99,999   9 (30)   5 (27.8) 
$100,000-$124,000   7 (23.3)   4 (22.2) 
$125,000-$149,999   5 (16.7)   3 (16.7) 
More than $150,000   5 (16.7)   3 (16.7) 
   
Highest Level of Education   
High School Graduate, 
Diploma, or Equivalent 
  2 (6.7)   1 (5.6) 
Some College, No Degree   2 (6.7)   1 (5.6) 
Associate Degree   5 (16.7)   3 (16.7) 
Bachelor’s Degree 15 (50) 11 (61.1) 
Master’s Degree   5 (16.7)   2 (11.1) 
Doctorate Degree   1 (3.3)   0 
   
Level of Infertility Insurance Coverage  
Partial Out-of-Pocket 17 (56.7)   9 (50) 
All Self-Pay 12 (40)   8 (44.4) 
Full Coverage   1 (3.3)   1 (5.6) 
   
Has At Least One Child   
No 24 (80) 14 (77.8) 
Yes   6 (20)   4 (22.2) 
   
Number of Prior Treatment Cycles at Current Clinic 
0-1 11 (36.7) 7 (38.9) 
2-3 14 (46.7) 7 (38.9) 
4 or greater   5 (16.7) 4 (22.2) 
Note. MEMS® = Medication Event Monitoring System. Total n=30. 
Participants who used MEMS® n= 18 
 
Primary Research Question 
 What do women undergoing infertility treatment perceive as barriers to and 
facilitators of MA that influence their medication-taking behaviors?  
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Hypothesis 1 
Women with higher MA barrier scores will demonstrate lower infertility MA scores 
than women with lower MA barrier scores. 
Medication adherence scores. A total of 18 (60%) of the 30 participants used 
MEMS® with infertility medication-taking for either one or two treatment cycles and 12 
(40%) participants did not use MEMS®. Reasons why participants either did not use 
MEMS® (n=12) or used MEMS® for only one treatment cycle (n=12) are described in the 
Flow Diagram in Figure 4.1. Of the 18 (60%) participants who used the MEMS®, 12 
(66.7%) women used MEMS® for one treatment cycle, and six (33.3%) women used 
MEMS® for two treatment cycles. 
  The median adherence MA score all 18 participants who used MEMS® score was 
0.975 (SD .078) with a range of 0.75 to 1.00. The median adherence rate of women who 
used MEMS® for two treatment cycles (n= 6) was .0975 (SD .060), and the median 
adherence score of women who used MEMS® for one treatment cycle (n= 12) was 0.95 (SD 
.087). There was no not significant difference (p= 0.616) in the median adherence scores 
between those who used MEMS® for one versus two treatment cycles.  
Medication adherence barrier scores. The barrier scores of ASK-20 Adherence 
Barrier Survey had a possible range of 20 to 100, with higher scores representing greater 
barriers to adherence. The mean total barrier score was 34.5 (SD 7.04) with a range of 25 to 
49 for all 30 participants. Of the 18 (60%) participants who used MEMS®, the median total 
barrier score was 34 (SD 7.18) with a range of 25 to 49. Of the 12 (40%) participants who 
did not use MEMS®, the median total barrier score was 35.5 (SD 6.96) with a range of 25 to 
42. There was no significant difference (p= 0.433) in the median total barriers scores 
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between those who used MEMS® and those who did not.  The most commonly reported 
barriers to medication-taking of the total sample (n=30) included recently feeling sad, down, 
or blue (53%, n=16), taking medication more than once per day (40%, n=12), forgetting 
things that were important (20%, n=6), worrying if the medication would affect sexual 
health (17%, n=5), and forgetting to take medication (10%, n=3). Regarding past 
medication-taking behaviors within the last week to three months, women reported taking 
medication more or less than prescribed (20%, n=6), not having the medication with them 
when it was time to take it (16.7%, n=5), and having skipped or stopped taking a medication 
because it made them feel bad (3.3%, n=1). Participant response percentages to the ASK-20 
Adherence Barrier Survey items are listed in Tables 4.3 and 4.4. Statistical significance was 
set at p < 0.05. There was a significant negative correlation (r = -.49; p=.020) between the 
total median barrier scores and MA the scores.  
Hypothesis 2 
Women with a greater number of perceived facilitators will demonstrate higher MA 
scores than women with a lesser number of perceived facilitators. 
Medication adherence scores and facilitators. The mean number of facilitators 
reported per participant was 3 (SD 1.41) with a range of 1 to 6 for all 30 participants. Of the 
18 (60%) participants who used MEMS®, the median number of facilitators reported per 
participant was 3 (SD 1.30) with a range of 1 to 6. Of the 12 (40%) participants who did not 
use MEMS®, the median number of facilitators reported was 2.5 (SD 1.60) with a range of 
1 to 6. There was no significant differences (p= 0.339) in the median number of reported 
facilitators between those who used MEMS® and those who did not. Emerging themes of  
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Table 4.3 
Responses to the ASK-20 Adherence Barrier Survey Concerning Medication Adherence Barriers by All Participants  
 % (n) 
Strongly 
Agree 
% (n) 
Agree 
% (n) 
Neutral 
% (n) 
Disagree 
% (n) 
Strongly 
Disagree 
I just forget to take my medicine some of the time. 3.3 (1) 6.7 (2) 3.3 (1)  13.3 (4) 73.3 (22) 
I run out of my medicine because I don’t get refills on time. 0 3.3(1) 3.3(1)          20 (6) 73.3 (22) 
My use of alcohol gets in the way of taking my medicines.  0 0 0 13.3(4) 86.7(26)  
I worry about how medicine will affect my sexual health. 0 16.7 (5) 13.3 (4) 13.3 (4) 56.7 (17) 
I sometimes forget things that are important to me. 0 20 (6) 3.3 (1)    36.7 (11) 40 (12) 
I have felt sad, down, or blue during the past month. 13.3 (4) 40 (12) 10 (3) 26.7 (8) 10 (3) 
I feel confident that each one of my medicines will help me. 26.7 (8) 53.3 (16) 16.7 (5) 3.3 (1) 0 
I know if I am reaching my health goals. 13.3 (4) 66.7 (20) 16.7 (5) 3.3 (1) 0 
I have someone I can call with questions about my medicines. 46.7 (14) 46.7 (14) 3.3 (1)  0 3.3 (1) 
I understand my doctor’s/nurse’s instructions about the 
medicines I take. 
 
60 (18) 40 (12)  0 0 0 
My doctor/nurse and I work together to make decisions. 46.7 (14)  40 (12) 13.3 (4) 0 0 
I am able to read and understand pill bottle labels. 73.3 (22) 23.3 (7) 3.3 (1) 0 0 
Taking medicines more than once a day is inconvenient. 6.7 (2) 33.3 (10) 13.3 (4) 26.7 (8) 20 (6) 
I have to take too many medicines a day. 0 20 (6) 13.3 (4) 26.7 (8) 40 (12) 
It is hard for me to swallow the pills I have to take. 0 6.7 (2) 0 23.3 (7) 70 (21)  
Note. n=30 
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Table 4.4 
Responses to the ASK-20 Adherence Barrier Survey Concerning Medication-taking Behaviors by All Participants 
 % (n) 
In the last 
week 
% (n) 
In the last 
month 
% (n) 
In the last 3 
months 
% (n) 
More than 
3 months 
ago 
% (n) 
Never 
Have you taken medicine more or less than prescribed? 
 
         10 (3)  3.3 (1)  6.7 (2)  6.7 (2)  73.3 (22) 
Have you skipped or stopped taking a medicine because you didn’t think 
it was working? 
 
        0  0  0  10 (3)  90 (27) 
Have you skipped or stopped taking a medicine because it made you feel 
bad? 
 
        0  0  3.3 (1)  16.7 (5)  80 (24) 
Have you skipped, stopped, not refilled, or taken less medicine because 
of cost? 
 
        0  0  0  6.7 (2)  93.3 (28) 
Have you not had medicine with you when it was time to take it? 
 
        0  10 (3)  6.7 (2)  30 (10)  53.3 (15) 
Note. n=30  
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 MA facilitators were categorized as (a) routine related, (b) physical aid 
related, (c) healthcare provider related, (d) knowledge related, (e) attitudes and beliefs 
related, (f) cognition related, (g) motivation related (h), control beliefs related, and (i) social 
support related. Routine related facilitators included associating pill-taking with a specific 
mealtime or taking pills after brushing teeth. Physical aid facilitators included activities such 
as placing pills in a location easily visible or using a mobile phone alarm as a reminder. 
Health provider related facilitators included receiving health provider instructions and 
feeling health provider optimism concerning treatment plan. Knowledge related facilitators 
included understanding about how the medicine works. Attitudes and beliefs related 
facilitators included thinking and hoping the medication will work. Cognition related 
facilitators included ability to remember to take medication.  
Motivation related facilitators included feeling a personal drive to take the medication. 
Control beliefs related facilitators included having a mental sense of control over 
circumstances. Social support related facilitators included partner reminders and having the 
support of important others. A detailed list of facilitators with participant response 
percentages is provided in Table 4.5. The most commonly reported facilitators categories 
were physical aid related (60%, n=18), routine related (50%, n=15), social support related 
(43%, n=13), and motivation related (27%, n=8). Statistical significance is set at p < 05. The 
correlation between the number of facilitators reported per participant and MA scores was 
not significant (r = -.02; p= 0.462). 
Hypothesis 3. 
Differences will exist among perceived barriers and facilitators between women who 
are adherent and non-adherent to their infertility medication regimen.  
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Table 4.5 
Medication Adherence Facilitator Thematic Categories Based on Data from All Participants  
Facilitator Type % 
Within Facilitator 
Category 
% 
Total Sample (n=30) 
Physical Related (n= 18)   60  
Using a mobile phone alarm (n=10)  55.5  
Placing pills at a location easily visible (n=9)  50  
Placing pills in medicine cabinet or pill box (n=6)  33.3  
Using a written schedule (e.g. personal diary) (n=2)  11.1  
Keeping pills in possession (e.g. purse) (n=1) 
 
 5.5  
Routine Related (n=15)   50 
Taking pills at mealtime or bedtime (n=11)  73.3   
Taking pills during a routine activity (e.g. brushing teeth) (n=2)  13.3  
Taking pills with other routine medications (e.g. prenatal vitamins) (n=4) 
 
 26.7  
Social Support Related (n=13)   43.3 
Partner reminders (n=10)  76.9  
Feeling support from important others (n=5)  38.4  
Hearing about the treatment success stories of other women (n=2) 
 
 15.4  
Motivation Related (n=8)   26.7  
Possessing sense of personal drive/motivation (n=8) 
 
 100  
Attitudes and Beliefs Related (n=6)   20 
Thinking the medication will work (n=3)  50  
Hoping the medication will work (n=3) 
 
 50  
Heath Care Provider Related (n=5)   16.7 
Health care provider instructions (n=4)  80  
Health care provider optimism (n=1) 
 
 20  
Table continues 
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Facilitator Type % 
Within Facilitator 
Category 
% 
Total Sample (n=30) 
Cognition Related (n=3)   10 
Ability to remember to take pills (n=3) 
 
 100  
Control Belief Related (n=2)   6.7 
Possessing sense of control over circumstances (n=2) 
 
 100  
Knowledge Related (n=1)   3.3 
Understanding how the medication works (n=1) 
 
 100  
Note. Total sample size = 30. Sample size varies within facilitator categories.
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Degree of adherence was dichotomized as follows: adherent group= MEMS® 
adherence score of 100% and non-adherent group= MEMS® adherence score of less than 
1.00. Of the 18 participants (60%) who used MEMS®, nine (50%) participants had an 
adherence rate of 1.00. The remaining nine participants (50%) had adherence scores ranging 
from 0.75 to 0.95 with a median rate of 0.90. Statistical significance is set at p < 0.05. 
Women in the non-adherent group had a significantly (p= 0.019) higher median total barrier 
score of 39.0 (SD= 6.49) compared to women in the adherent group with an median total 
barrier score of 30.0 (SD= 5.79). Tables 4.6 and 4.7 present ASK-20 Adherence Barrier 
Survey item response percentages based on women who were adherent to their infertility 
medication regimen. Tables 4.8 and 4.9 present ASK-20 Adherence Barrier Survey item 
response percentages based on women who were non-adherent to their infertility medication 
regimen.  
 No significant difference was observed with the number of perceived facilitators 
reported between women who were adherent and women who were non-adherent. The group 
who were adherent had a median of 3.00 (SD 1.20) facilitators with a range of 2 to 5 
facilitators, and the group who were non-adherent had a median of 3.00 (SD 1.45) 
facilitators with a range of 1 to 6 facilitators. There were no significant differences found in 
types of facilitators reported between the two groups of women. Table 4.10 presents 
facilitators and participant response percentages based on women who were adherent to their 
infertility medication regimen. Table 4.11 presents facilitators and participant response 
percentages based on women who were non-adherent to their infertility medication regimen. 
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Table 4.6 
Responses to the ASK-20 Adherence Barrier Survey Concerning Medication Adherence Barriers by Participants Who Were 
Adherent 
 % (n) 
Strongly 
Agree 
% (n) 
Agree 
% (n) 
Neutral 
% (n) 
Disagree 
% (n) 
Strongly 
Disagree 
I just forget to take my medicine some of the time. 0 0 0 0 100(9) 
I run out of my medicine because I don’t get refills on time. 0 0 11.1 (1) 11.1 (1) 77.8 (7) 
My use of alcohol gets in the way of taking my medicines. 0 0 0 0 100 (9) 
I worry about how medicine will affect my sexual health. 0 11.1 (1) 11.1 (1) 11.1 (1) 66.7 (6) 
I sometimes forget things that are important to me. 0 11.1 (1) 0 33.3 (3) 55.6 (5) 
I have felt sad, down, or blue during the past month. 11.1 (1) 22.2 (2) 11.1 (1) 33.3 (3) 22.2 (2) 
I feel confident that each one of my medicines will help me. 33.3 (3) 66.7 (6) 0 0 0 
I know if I am reaching my health goals. 22.2 (2) 33.3 (3) 44.4 (4) 0 0 
I have someone I can call with questions about my medicines. 44.4 (4) 55.6 (5) 0 0 0 
I understand my doctor’s/nurse’s instructions about the 
medicines I take. 
 
55.6 (5) 44.4 (4) 0 0 0 
My doctor/nurse and I work together to make decisions. 44.4 (4) 55.6 (5) 0 0 0 
I am able to read and understand pill bottle labels. 77.8 (7) 22.2 (2) 0 0 0 
Taking medicines more than once a day is inconvenient. 0 11.1 (1) 33.3 (3) 33.3 (3) 22.2 (2) 
I have to take too many medicines a day. 0 22.2 (2) 0 22.2 (2) 55.6 (5) 
It is hard for me to swallow the pills I have to take. 0 11.1 (1) 0 22.2 (2) 66.7 (6) 
Note. n=9 
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Table 4.7 
Responses to the ASK-20 Adherence Barrier Survey Concerning Medication-taking Behaviors by Participants Who Were 
Adherent  
 % (n) 
In the last 
week 
% (n) 
In the last 
month 
% (n) 
In the last 3 
months 
% (n) 
More than 
3 months 
ago 
%( n) 
Never 
Have you taken medicine more or less than prescribed? 
 
 22.2 (2)  0  0  0  77.8(7) 
Have you skipped or stopped taking a medicine because you didn’t think 
it was working? 
 
 0  0  0  0  100 (9) 
Have you skipped or stopped taking a medicine because it made you feel 
bad? 
 
 0  0  0  22.2 (2)  77.8 (7) 
Have you skipped, stopped, not refilled, or taken less medicine because 
of cost? 
 
 0  0  0  0  100 (9) 
Have you not had medicine with you when it was time to take it? 
 
 0  0  11.1 (1)  22.2 (2)  66.7 (6) 
Note. n=9 
  
  
7
4
 
Table 4.8 
Responses to the ASK-20 Adherence Barrier Survey Concerning Medication Adherence Barriers by Participants Who Were Non-
adherent 
 % (n) 
Strongly 
Agree 
% (n) 
Agree 
% (n) 
Neutral 
% (n) 
Disagree 
% (n) 
Strongly 
Disagree 
I just forget to take my medicine some of the time. 0 11.1 (1) 11.1 (1) 11.1 (1) 66.7 (6) 
I run out of my medicine because I don’t get refills on time. 0 0 0 44.4 (4) 55.6 (5) 
My use of alcohol gets in the way of taking my medicines. 0 0 0 33.3(3) 66.7(6) 
I worry about how medicine will affect my sexual health. 0 22.2 (2) 22.2 (2) 22.2 (2) 33.3 (3) 
I sometimes forget things that are important to me. 0 22.2 (2) 0 44.4 (4) 33.3 (3) 
I have felt sad, down, or blue during the past month. 0 55.6 (5) 0 33.3 (3) 11.1 (1) 
I feel confident that each one of my medicines will help me. 11.1 (1) 44.4 (4) 44.4 (4) 0 0 
I know if I am reaching my health goals. 0 88.9 (8) 11.1 (1) 0 0 
I have someone I can call with questions about my medicines. 22.2 (2) 55.6 (5) 11.1 (1) 0 11.1 (1) 
I understand my doctor’s/nurse’s instructions about the 
medicines I take. 
 
33.3 (3) 66.7 (6) 0 0 0 
My doctor/nurse and I work together to make decisions. 11.1 (1) 66.7 (6) 22.2 (2) 0 0 
I am able to read and understand pill bottle labels. 55.6 (5) 33.3 (3) 11.1 (1) 0 0 
Taking medicines more than once a day is inconvenient. 11.1 (1) 44.4 (4) 11.1 (1) 33.3 (3) 0 
I have to take too many medicines a day. 0 33.3 (3) 11.1 (1) 44.4 (4) 11.1 (1) 
It is hard for me to swallow the pills I have to take. 0 11.1 (1) 0 44.4 (4) 44.4 (4) 
Note. n=9 
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Table 4.9 
Responses to the ASK-20 Adherence Barrier Survey Concerning Medication-taking Behaviors by Participants Who Were Non-
adherent  
 % (n) 
In the last 
week 
% (n) 
In the last 
month 
% (n) 
In the last 3 
months 
% (n) 
More than 
3 months 
ago 
% (n) 
Never 
Have you taken medicine more or less than prescribed? 
 
0 0 11.1 (1) 11.1 (1) 77.8 (7) 
Have you skipped or stopped taking a medicine because you didn’t think 
it was working? 
 
0 0 0 22.2(2) 77.8 (7) 
Have you skipped or stopped taking a medicine because it made you feel 
bad? 
 
0 0 11.1 (1) 33.3 (3) 55.6 (5) 
Have you skipped, stopped, not refilled, or taken less medicine because 
of cost? 
 
0 0 0 22.2 (2) 77.8 (7) 
Have you not had medicine with you when it was time to take it? 
 
0 11.1 (1) 11.1 (1) 55.6 (5) 22.2 (2) 
Note. n=9 
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Table 4.10 
Medication Adherence Facilitator Thematic Categories Based on Data from Participants Who Were Adherent  
Facilitator Type % Within 
Facilitator 
Category 
% Total 
Sample (n=9) 
Physical Related (n=6)   66.6 
Placing pills at a location easily visible (n=1)    16.7  
Placing pills in medicine cabinet or pill box (n=1) 16.7  
Keeping pills in possession (e.g. purse) (n=0)     0  
Using a mobile phone alarm (n=5) 83.3  
Using a written schedule (e.g. personal diary) (n=2) 
 
33.3  
Social Support Related (n=6)   66.6 
Partner reminders (n=5) 83.3  
Feeling support from important others (n=0)     0  
Hearing about the treatment success stories of other women (n=1) 
 
16.7  
Attitudes and Beliefs Related (n=4)   44.4 
Thinking the medication will work (n=2) 50  
Hoping the medication will work (n=2) 
 
50  
Routine Related (n=4)   44.4 
Taking pills at mealtime or bedtime (n=3) 75  
Taking pills during a routine activity (e.g. brushing teeth) (n=1) 25  
Taking pills with other routine medications (e.g. prenatal vitamins) (n=0) 
 
0  
Motivation Related (n=3)   33.3 
Possessing sense of personal drive/motivation (n=3) 
 
100  
Heath Care Provider Related (n=2)   22.2 
Health care provider instructions (n=2) 100  
Health care provider optimism (n=0) 0  
Being involved in plan of care (n=0) 0  
Table continues 
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Facilitator Type % Within 
Facilitator 
Category 
% Total 
Sample (n=9) 
Control Belief Related (n=1)   11.1 
Possessing sense of control over circumstances 
 
100  
Knowledge Related (n=0)   0 
Understanding how the medication works (n=0) 
 
0  
Cognition Related (n=0)   0 
Ability to remember to take pills (n=0) 
 
0  
Note. Total sample size = 9. Sample size varies within facilitator categories.  
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Table 4.11 
Medication Adherence Facilitator Thematic Categories Based on Data from Participants Who Were Non-adherent  
Facilitator Type % Within 
Facilitator 
Category 
% Total Sample 
(n=9) 
Routine Related (n=7)   77.8  
Taking pills at mealtime or bedtime (n=6)  85.8  
Taking pills during a routine activity (e.g. brushing teeth) (n=1)  14.3  
Taking pills with other routine medications (e.g. prenatal vitamins) (n=2) 
 
 28.6  
Social Support Related (n=5)   55.6 
Partner reminders (n=2)  40  
Feeling support from important others (n=3)  60   
Hearing about the treatment success stories of other women (n=1) 
 
 20  
Physical Related (n=4)   44.4 
Placing pills at a location easily visible (n=2)  50  
Placing pills in medicine cabinet or pill box (n=1)  25  
Keeping pills in possession (e.g. purse) (n=0)  0  
Using a mobile phone alarm (n=1)  25  
Using a written schedule (e.g. personal diary) (n=0) 
 
 0  
Heath Care Provider Related (n= 2)   22.2 
Health care provider instructions (n=2)  100  
Health care provider optimism (n=0)  0  
Being involved in plan of care (n=0) 
 
 0  
Motivation Related (n=2)   22.2 
Possessing sense of personal drive/motivation (n=2) 
 
 100  
Attitudes and Beliefs Related (n=1)   11.1 
Thinking the medication will work (n=1)  100  
Hoping the medication will work (n=0)  0  
Table continues 
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Facilitator Type % Within 
Facilitator 
Category 
% Total Sample 
(n=9) 
Cognition Related (n=1)   11.1 
Ability to remember to take pills (n=1) 
 
 100  
Control Belief Related (n=1)   11.1 
Possessing sense of control over circumstances (n=1) 
 
 100  
Knowledge Related (n=0)   0 
Understanding how the medication works (n=0) 
 
  
Note. Total sample size = 9. Sample size varies within facilitator categories. 
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Secondary Research Question 
  What background factors and personal experiences with infertility treatment are 
associated perceived barriers of and facilitators to MA among women undergoing infertility 
treatment?  
Hypothesis 4 
Differences will exist in women’s personal experiences with infertility treatment 
based on women’s age, race/ethnicity, level of education, income, and infertility insurance 
status. 
 Broader themes that emerged concerning personal experiences with infertility 
treatment included (a) individual experiences, (b) social support experiences, and 
(c) treatment concern experiences. Individual experiences were categorized into (1) feelings 
of self-blame, (2) feelings of emotional distress, (3) feelings of psychological distress, 
(4) positive view on treatment success, and (5) negative view on treatment success. Social 
support experiences was categorized into (1) having a supportive partner, (2) having a broad 
support system, and (3) feeling a need for greater public awareness and open discussions 
regarding infertility. Treatment concern experiences were categorized into (1) concerns 
about health risks, (2) concerns about treatment outcomes, and (3) concerns about financial 
burden. Table 4.12 provides a detailed list of personal experience thematic categories with 
participant response percentages. 
 Background factor variables and the relationship to personal experiences with 
infertility treatment are provided with p-values in Table 4.13. Statistical significance is set at 
p < 0.05. Statistically significant values are signified with an asterisk. There was a  
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Table 4.12 
Personal Experiences Thematic Categories Based on Data from All Participants  
Personal Experiences % 
Total Sample (n = 30) 
Individual Experiences  
Feelings of Self Blame (n=3)  10 
Feelings of Emotional Distress (n=17)  56.7 
Feelings of Psychological Distress (n=11)  36.6 
Positive View on Treatment Success (n=9)  30 
Negative View on Treatment Success (n=8)  26.6 
Social Support Experiences  
Supportive Partner (n=18)  60 
Broader Support System (n=24)  80 
Need for Infertility Public Awareness (n=7)  23.3 
Treatment Concern Experiences  
Concerns about Health Risks (n=10)  33.3 
Concerns about Treatment Outcomes (n=12)  40 
Concerns about Financial Burden (n=10)  33.3 
 
significant correlation (0.56; p= 0.049) between women’s race and feelings of self-blame for 
having fertility problems. Caucasians and African-American women had a higher 
probability of reporting feelings of self-blame. Asian, Hispanic, and Native American 
women had a lower probability of reporting feelings of self-blame.  
 There was a significant correlation (0.56; p= 0.010) between number of prior failed 
treatment cycles and women experiencing feelings of emotional distress. Women who had 
reported zero to one previous failed treatment cycles had a lower probability of experiencing 
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Table 4.13 
P-values Explaining the Relationship between Demographic Factors and Personal Experiences with Infertility Treatment 
Personal Experience Age 
Group 
Race Education Income Residential 
Community 
Prior 
Child 
Infertility 
Insurance 
Status 
Number of 
Previous 
Failed 
Cycles 
Individual Experiences         
Feelings of Self Blame .369 .049* .649 .609 .717 .361 .599 .653 
Feelings of Emotional Distress .043 .635 .237 .369 .105 .197 .373 .010* 
Feelings of Psychological Distress .711 384 .742 .121 .176 .850 .407 .985 
Positive View on Treatment Success .193 .702 .586 .092 .047* .680 .180 .202 
Negative View on Treatment Success .909 .199 .722 .594 .631 .842 .139 .355 
Social Support Experiences         
Supportive Partner .364 .199 .108 .222 .933 .015* .516 .385 
Broader Support System .679 .061 .526 .141 .392 .171 .331 .352 
Need for Infertility Public Awareness .799 .341 .788 .888 .424 .666 .621 .424 
Treatment Concern Experiences         
Concerns about Health Risks .574 .767 .168 .334 .223 .333 .609 .281 
Concerns about Treatment Outcomes .364 .119 .337 .710 .103 .709 .078 .601 
Concerns about Financial Burden .972 .767 .654 .381 .583 .100 .767 .193 
Note. Sample size=30. P-values are based on Chi-Square Test calculations. Significance was set at 0.05.  
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feelings of emotional distress. Women who reported having two to three previous failed 
treatment cycles had a higher probability of reporting feelings of emotional distress. There 
was a significant correlation (0.45; p= 0.047) between women’s place of residence and 
holding a positive view regarding infertility treatment success. Women who lived in urban 
and rural communities had a higher probability of having a positive outlook on treatment 
success. Women who lived in suburban communities had a lower probability of having a 
positive outlook on treatment success.  
 There was a significant correlation (-0.44; p= 0.015) between women who already 
had children and having a supportive partner. Women who had at least one prior child had a 
lower probability of reporting a supportive partner. Women who were childless had a higher 
probability of reporting a supportive partner. The correlation between having a prior child 
and reporting a supportive partner was -0.44. There were no significant relationships 
between age, ethnicity, level of income, infertility insurance status, and women’s personal 
experiences with infertility treatment.  
Hypothesis 5 
Differences will exist between adherent and non-adherent women by age, race, 
ethnicity, level of education, income, and infertility insurance status. 
 There were no significant differences between women who were adherent and 
women who were non-adherent based on demographic factors. Table 4.14 provides 
background factor variables and the corresponding relationship to adherence in p-values. 
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Table 4.14 
 
P-values Explaining Relationship between Background Factors and Adherence 
Background Factor Adherent versus Non-
adherent (n=18) 
Age Group .767 
Race .381 
Ethnicity  .303 
Education .352 
Income .301 
Residential Community .325 
Prior Child .257 
Infertility Insurance Status .574 
Number of Previous Failed Cycles .053 
 
Note. P-values are based on Chi-Square Test calculations. Significance was set at 0.05.  
Exploratory Research Question 
How do women’s personal experiences with infertility treatment influence MA 
behaviors? 
Exploratory Hypothesis 
Differences will exist between women who are adherent and women who are non-
adherent based on women’s personal experiences with undergoing infertility treatment. 
 Women who were adherent were significantly more likely to have a positive view on 
treatment success, and women who were nonadherent were more likely to not have a 
positive view on treatment success (0.62; p= 0.009). There were no significant differences 
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between the two groups of women based on other personal experiences. Table 4.15 provides 
participant response percentages to the thematic categories of personal experiences with 
infertility treatment and the relationship between women who were adherent and women 
who were not adherent to infertility medication. 
Table 4.15 
Personal Experiences Thematic Categories Based on Adherence  
Personal Experiences Total Adherent 
n (%) 
Total 
Non-adherent 
n (%) 
Individual Experiences   
Feelings of Self Blame 0 (0) 2 (22.2) 
Feelings of Emotional Distress 5 (55.6) 5 (55.6) 
Feelings of Psychological Distress 3 (33.3) 4 (44.4) 
Positive View on Treatment Success 5 (55.6)* 1 (11.1)* 
Negative View on Treatment Success 2 (22.2) 3 (33.3) 
Social Support Experiences   
Supportive Partner 7 (77.8) 5 (55.6) 
Broader Support System 7 (77.8) 7 (77.8) 
Need for Infertility Public Awareness 2(22.2) 4 (44.4) 
Treatment Concern Experiences    
Concerns about Health Risks 2 (22.2) 5 (55.6) 
Concerns about Treatment Outcomes 3 (33.3) 3 (33.3) 
Concerns about Financial Burden 2 (22.2) 2 (22.2) 
Note. Total adherent: n=9. Total non-adherent: n=9. P-values are based on Chi-
Square Test calculations. Significance was set at 0.05 indicated by *. 
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Post Hoc Analysis 
A post hoc analysis was conducted to determine if there was a correlational 
relationship between women’s self-report of infertility MA and their actual medication-
taking behaviors. 
Analysis plan. The assumption of normality was not met for the distribution of MA 
scores based on the small sample size (n=18) that used MEMS®. Thus Spearman’s rho 
correlation coefficient was computed to assess the relationship between the five behavior-
focused items on the ASK-20 Adherence Barrier Survey (independent variable) and MA 
scores (dependent variable) and the MA scores at a significance level of .05. 
Higher ASK-20 Adherence Barrier Survey scores for the five MA behavior-focused 
items indicated a higher degree of infertility MNA. Statistical significance was set at p < 
0.05. There was a significant negative correlation (-.49; p=.020) between participant self-
report of MNA barrier scores and MA scores.   
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CHAPTER 5 
DISCUSSION 
 Chapter 5 includes a robust discussion of study findings, strengths, limitations, 
implications for future studies, and conclusion. The purpose of the B-NFORMED study was 
to identify specific barriers to and facilitators of infertility MA while documenting women’s 
actual medication-taking behaviors. This study has provided deeper insight concerning the 
misconception that who undergo infertility treatment are fully adherent to their infertility 
medication regimen. Although the median MA score of the 18 (60%) participants who used 
medication electronic monitoring appeared very high at 0.98, half (50%) of these women 
had variable MA scores that ranged from 0.75 to 0.95, and the other half (50%) of the 
women had a 1.00 MA score, which raised the overall MA rate. Because previous studies 
have not documented infertility MA scores of less than 1.00 to achieve optimal reproductive 
outcomes, a MA threshold score of 1.00 was chosen to divide the adherers from the non-
adherers. As such, the MA adherence patterns found in this study are in alignment with 
known oral infertility MA behaviors (Mahoney et al., 2019) and general MA behaviors 
(Sabaté & World Health Organization, 2003) across broader patient populations.  
 Letrozole was the medication monitored in this study for 17 of 18 (94.4%) 
participants. Clomiphene citrate was used by only one (5.5%) participant. Both medications 
were prescribed once daily for a 5-day treatment course per cycle. Letrozole is a well-known 
treatment for breast cancer in postmenopausal women and is commonly used for infertility 
treatment (ovulation induction) based on its antiestrogenic properties (Kar, 2013). 
Clomiphene citrate is primarily used for infertility treatment (ovulation induction) and other 
hormonal conditions due to its antiestrogenic properties (Kar, 2013). Yet, the dose-
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dependent efficacy on pregnancy rates and surrogate measures of infertility treatment 
effectiveness (e.g., follicular development, changes in hormone levels, cervical mucus 
quality, and ovulation) has not been established for either letrozole or clomiphene citrate. 
Prior studies have compared the uses or letrozole and clomiphene citrate for ovulation 
induction, although MA behaviors have not been the focus of this research (Bequm, 
Ferdous, Bequm, & Quadir, 2009; He & Jiang, 2011). Although pregnancy rates were not 
the current study outcome, examining infertility MA behaviors should be an important step 
to accomplishing pregnancy. 
 With respect to Vrijens and colleagues’ (2012) proposed taxonomy for defining MA 
(initiation, implementation, discontinuation, and persistence), all 18 women who used the 
MEMS® attained successful initiation of letrozole and clomiphene citrate. None of them 
discontinued the medication early. However, non-adherence occurred during the 
implementation phase, when the women’s actual dosing behaviors were not in alignment 
with the prescribed dosing regimen. The women were advised by the infertility providers to 
take the medication at the same time every day, and they were provided a two-hour window 
with the MEMS®. Still, all 18 women persisted through the five-day completion period for 
letrozole and clomid.  
 The entire sample (n=30) of women enrolled in the B-NFORMED study identified 
several barriers and facilitators to following their prescribed infertility medication regimens. 
More than half (53%) responded in agreement to currently feeling sad, down, or blue on the 
ASK-20 Adherence Barrier Survey. Depression has been shown to worsen people’s 
medication taking patterns (Gellad, Grenard, & McGlynn, 2009). Depression and anxiety is 
more prevalent in women with infertility compared to women without infertility (Lakatos, 
 89 
Szigeti, Ujma, Sexty, & Balog, 2017). In fact, depression and anxiety are well understood to 
elevate stress levels for women undergoing infertility treatment (Ogawa, Takamatsu, & 
Horiguchi, 2011; Prasad, Kumar, Nayar1, Prasad, & Sharma, 2017; Rooney & Domar, 
2018). Furthermore, newer research has shown that higher stress levels could compromise 
infertility treatment outcome, which demonstrates a reciprocal process (Rooney & Domar, 
2018). Thus, innovative psychological interventions have been tested and have been shown 
to reduce psychological distress, which has subsequently resulted in higher pregnancies rates 
during infertility treatment (Chow, Cheung, & Cheung, 2016; Frederiksen, Farver-
Vestergaard, Skovgård, Ingerslev, & Zachariae, 2015).  This raises the question if 
psychological interventions used in prior studies could have also positively impacted 
women’s MA behaviors.  The relationship between depression and infertility MA had not 
been investigated prior to this study.   
 All medications monitored in this study were prescribed for once daily dosing. Still, 
40% (n=12) of the 30 total participants responded that taking medication more than once per 
day was a barrier to MA. This raises suspicion that women may have considered additional 
prescribed medications when taking the ASK-20 Barrier Adherence Survey although the PI 
instructed participants to concentrate solely on infertility medications. Seventeen percent 
(n=5) of women reported concern about medication affecting sexual health as a barrier, 
substantiating prior literature that women receiving infertility treatment experience 
difficulties with their sexuality (Tao, Coates, & Maycock, 2011).  
  When comparing group differences with perceived barriers, women who were 
adherent to their infertility MA regimen had significantly (p=0.019) higher MA barrier 
scores compared to women who were non-adherent (39 versus 30). Yet, the mean MA 
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barrier score (34.5) on the ASK-20 Adherence Survey did not approach the maximum score 
(100) on the total barrier score continuum. Nonetheless, women with a perceived higher 
degree of barriers had significantly (r = -.49, p=0.020) lower MA rate compared to women 
with a perceived lower degree of barriers—yielding a negative correlation with a large effect 
size of 0.24. These findings are analogous to previous studies that used the ASK-20 
Adherence Survey to assess MA barriers and MA patterns in other patient populations 
(Martza et al., 2008; Rolnick, Asche, Pawloski, Bruzek, & Hedblom, 2013). In patients with 
asthma, for example, Atsuta et al. (2017) found a high correlation of -.51 between mean 
ASK-20 Adherence Barrier Survey total scores and MA scores with a much larger sample 
size (n= 290) than the B-NFORMED study.  
 Women enrolled in the current study cited a host of facilitators to infertility MA, 
while the majority (60%) cited physical aid related factors (e.g., placing pills where easily 
visible, using a medication cabinet or pill box, using a mobile phone alarm). The other most 
common facilitators reported were routine (50%), social support (43%), and motivation 
related (27%). Nevertheless, the relationship between the number and types of facilitators 
reported by women were not significant when correlated with their corresponding MA 
scores. 
  This finding raises inquiry if MA facilitators in this population could be highly 
individualized in magnitude and effect on adherence behaviors, such that grouping women 
by common facilitators may have been a more daunting task than conceptualized. This may 
explain the absence of psychometrically sound instruments in the literature that capture the 
construct of MA facilitators like that of MA barrier scales. Accordingly, qualitative methods 
have been traditionally employed to investigate people’s perceived facilitators to MA 
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highlighting the uniqueness that each participant offers when generating this type of study 
data (Castro et al., 2015; Claes et al., 2014; Curioso et al., 2010; Ho et al., 2017).  
 Background factors such as age, race, education, income, and health insurance status 
have influenced medication-taking behaviors in various patient populations (Cho & Kim, 
2014; Conn et al., 2015; Conn, Ruppar, Enriquez, & Cooper, 2015; Kilgore et al., 2016; 
Park, Howie-Esquivel, & Dracup, 2014; Whittle et al., 2016). In the B-NFORMED study, 
there were no significant demographic differences found in relation to MA behaviors, yet 
samples demographics were largely homogeneous. Concerning presence of insurance 
coverage and out-of-pocket expenses for infertility treatment services, all (96.7%) but one 
(3.3%) participant reported either having partial responsibility or bearing full out-of-pocket 
pay responsibility. Therefore, discriminating between demographic variables of women who 
were adherent and who were non-adherent was a difficult task, although the sample 
demographics are in alignment with national statistics for this population (Kessler, Craig, 
Plosker, Reed, & Quinn, 2014).  
 Medication cost was not a cited barrier to MA based on women’s responses on the 
ASK-20 Adherence Barrier Survey. This could have occurred based on the fact that oral 
medications (letrozole and clomiphene citrate) are modestly priced compared to injection 
medications. In addition, infertility treatment involves an array of other services that are 
independent of medication costs (e.g., laboratory tests, transvaginal ultrasounds, intrauterine 
insemination procedure) (ASRM, 2012b). Furthermore, if infertility treatment progresses to 
more advanced modalities such as IVF, the associated costs can steeply skyrocket (Katz 
et al., 2011). During the structured interviews when women in the current study were asked 
about treatment concerns, 10 (33.3 %) of them cited financial burden.  
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         Social support and health care provider support were assessed as both barriers and 
facilitators in the B-NFORMED study. The literature has classified social support into two 
types: (a) structural support (e.g., marital status, living arrangement) and (b) functional 
support—which is further differentiated into instrumental/practical support (e.g., picking up 
prescriptions, reading labels) and emotional support (e.g., encouragement, listening) 
(DiMatteo, 2004; Scheurer, Choudhry, Swanton, Matlin, & Shrank, 2012). Of the total 30 
participants, all were married and cohabited with their spouses. Only one (3.3%) woman 
cited inadequate help from others with medication-taking. Thirteen (43.3%) participants 
reported instrumental and emotional type support with medication-taking behaviors, and 
women without children were significantly (p=0.015) more likely to report having a 
supportive partner compared to women who already had a child. However, no significant 
differences were found between women who were adherent and women who were non-
adherent to their infertility medication with respect to social support.  
  Women undergoing infertility treatment have reported a preference to shared 
decision-making with their health care provider (Boivin et al., 2012). In the B-NFORMED 
study, the majority of participants reported positive health care provider related support-
based responses to the ASK-20 Adherence Barrier Survey and structured interviews. 
Nonetheless, four (13.3%) participants felt neutral concerning working with the health care 
provider in making shared decisions. Still, no significant differences were found between 
women who were adherent and women who were non-adherent to their infertility 
medication with respect to health provider support.  
 Infertility treatment takes an emotional toll on women (Gameiro et al., 2015). In the 
current study, Caucasian and African-American women were more likely to report feelings 
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of self-blame for having infertility compared to Asian, Hispanic, and Native American 
women.  However, since the majority of participants were Caucasian, which served as the 
reference (nominal) variable for race in the analysis, caution should be taken when 
interpreting these findings for non-Caucasian women.  Interestingly, regardless of race, 
research has shown that infertility treatment is associated with higher levels of emotional 
distress than having the infertility diagnosis itself (Greil, McGuillan, Lowry, & Shreffler, 
2011). Women in the current study who experienced prior failed treatment cycles were 
significantly (p=0.010) associated with experiencing feelings of emotional distress.  
 Women’s personal experiences with infertility treatment has been shown to impact 
their decisions about treatment discontinuation (Domar et al., 2018; Gameiro et al., 2012; 
Gameiro et al., 2013). Seven (23.3%) participants in the B-NFORMED study decided to 
either suspend or discontinue infertility treatment. Early treatment discontinuation is 
generally considered a primary determining factor of treatment ineffectiveness, yet many 
women choose to discontinue infertility treatment, including women with infertility 
insurance coverage (Domar et al., 2018; Gameiro et al., 2012). Although there are no clear 
indicators for infertility treatment discontinuation, treatment rejection has been considered a 
possible causative factor for some women (Gameiro et al., 2012; Gameiro et al., 2013; 
Olivius et al., 2004). In the current study, women who lived in suburban communities and 
women who were non-adherent to their infertility treatment regimen were less likely to have 
a positive view on treatment success. These findings raise speculation if women’s level of 
enthusiasm concerning treatment outcomes influences their decision to discontinue 
treatment. Moreover, the relationship between infertility treatment outcomes, early treatment 
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discontinuation, and MNA will be of particular interest when developing future 
interventions. 
 Advances in healthcare research and treatment ingenuity have contributed to a 
paradigm shift that emphasizes customized treatment based on individuals’ needs 
(Agyeman, Ofori-Asenso, 2015; Vogenburg, Barash, & Pursel, 2010). Because many 
treatment modalities incorporate prescription medications, researchers have now directed 
attention at understanding determinants of MA and identifying predictors of MA (Kardas, 
Lewek, & Matyjaszczyk, 2013). Prediction of MA behavior remains a challenge for two 
reasons: (1) multifaceted determinants of MA are present, and (2) the factors surrounding 
these determinants vary among populations (e.g., senior adults, female hormonal 
contraception, individuals with HIV, diabetes, and hypertension) (Kardas et al., 2013; 
Kazerooni, Takizawa, & Vu, 2014; Kirkman et al., 2015; Krousel-Wood, Muntner, Islam, 
Morisky, & Webber, 2009; Rodgers et al., 2018; Thames et al., 2012). Thus, identifying 
determinants and predictors of MA among women with infertility may be an additional 
challenge.  
Strengths 
 This novel study used a mixed methods approach to identify what women perceived 
as barriers to and facilitators of infertility MA. The mixed methods methodology synergized 
interview data with questionnaire data to generate new knowledge in reproduction science. 
Infertility medication-taking patterns were followed with the MEMS® instrument to 
determine if individual differences in perceived barriers and facilitators between women 
influenced their actual behaviors. The use of the MEMS® instrument offered a highly 
reliable and valid means to determine at which phase (initiation, implementation, and 
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discontinuation) infertility MNA occurred. Because little is known concerning how the 
burden of having infertility and undergoing infertility treatment impacts subsequent MNA, 
the B-NFORMED study offers a unique foundation for future investigation.  
Limitations 
 Several factors limited generalizability of the study findings. The setting was a single 
site practice, whereas multiple clinics could have broadened participant recruitment. The 
study sample was largely homogenous. All participants were married and the majority were 
Caucasian, college-educated, and lived in suburban communities. Only 18 (60%) of 30 
women used the MEMS®, compromising the study’s power to discriminate true differences 
in barrier and facilitator variables between women who were adherent and women who were 
non-adherent. The convenience sampling approach increased opportunity for sampling bias. 
Selection bias was a concern because there was no means to determine demographic 
differences between those who participated in the study and those who declined 
participation. Lastly, there is uncertainty about the degree to which women responded to 
ASK-20 Adherence Barrier Survey items based on other prescription medications additional 
to infertility medication.  
Implications for Future Research 
 The findings of the B-NFORMED study have theory, research, practice, and policy 
implications. Fishbein and Ajzen’s (2010) Reasoned Action Model purports that perceived 
barriers to and facilitators of performing a behavior can impact one’s intention to perform 
that behavior. In accordance with this theory, the B-NFORMED study demonstrated that a 
greater amount of perceived barriers to infertility MA influences women’s medication-
taking behaviors. Yet, there is still uncertainty about how perceived MA facilitators impact 
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infertility MA. Future studies are needed to determine the type and magnitude of facilitators 
that could influence women’s intention to adhere to prescribed infertility medication 
regimens. Understanding the relationship between infertility treatment discontinuation and 
MNA will be important. Also, theory-driven investigations will be beneficial to explain 
determinants and predictors of infertility MA.  Further, interventions that implement 
counseling methods such as motivational interviewing should be considered to reduce 
women’s psychological and emotional distress, and improve MA during infertility treatment 
cycles.  
 The B-NFORMED study revealed oral MNA behaviors with merely once a day 
medication dosing schedules.  Future research should concentrate on oral and injection MA 
patterns during IUI and IVF cycles when medication schedules become more complex, 
which could elevate the risk for infertility MNA.  Moreover, based on the post hoc analysis 
of this study, which significantly correlated women’s self-report of MA with their actual 
infertility medication-taking patterns, implementation of a brief  MA assessment in clinical 
practice could identify those needing assistance to improve their MA behaviors.  Additional 
studies are needed to fully understand how infertility non-adherence behaviors affects 
pregnancy outcomes. The development and testing of innovative interventions will be 
necessary to overcome MNA not only in practice but during future clinical trials that 
evaluate the treatment effectiveness of new and existing infertility medications. Non-
adherence behaviors during infertility medication clinical trials compromises study power, 
reduces treatment effect size, and weakens overall study findings.  
 In this era of personalized medication, more research is focused on tailoring 
infertility pharmacotherapies to women based their genetic characteristics to optimize 
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treatment outcomes (Kalinderi, Asimakopoulos, Nikolettos, & Manuolopulos, 2018). Still, 
the benefits of these therapies are dependent upon women’s adherence to the regimen. 
Future studies are needed that incorporate women’s personal needs into clinical trials and 
clinical practice guidelines. In the B-NFORMED study, women frequently reported feelings 
of psychological and emotional burden while undergoing infertility treatment. Gaining 
knowledge about how treatment burden influences infertility medication-taking can assist 
health care providers with making better treatment decisions.  
 With advancements in reproduction science, women who would ordinarily remain 
childless have been able build families. Yet, there are many women who do not have access 
to infertility treatment due to lack of a covered benefit for these services. Meanwhile, 
national policy discussions remain in debate concerning expansion for infertility services in 
the U.S. The majority of women in the B-NFORMED study did not have full health 
insurance coverage for infertility treatment services. Several of them reported that treatment 
cost was a major concern, particularly if treatment had progressed to IVF. Therefore, future 
studies testing cost-effective interventions to improve women’s infertility MNA could 
influence lawmakers’ decisions for implementing new policies that mandate infertility 
insurance coverage options to women nationwide.  
Conclusion 
 The B-NFORMED study has identified women’s perceived barriers to and 
facilitators of MA while undergoing infertility treatment and described those that were 
associated with women’s actual MA behaviors. The findings of this study offer new insight 
about this unique population that could impact the future of clinical practice. This study 
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serves as a framework to cultivate ongoing scientific discovery including forthcoming 
interventional studies aimed at optimizing infertility MA behaviors.  
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APPENDIX A 
FISHBEIN AND AJZEN’S REASONED ACTION MODEL 
 
(Fishbein & Ajzen, 2010) 
This model asserts that intention determines the likelihood of behavior performance. 
 
• Background factors are considered to influence how information is recalled and 
interpreted, which impacts beliefs about performing a behavior. 
• Behavioral beliefs are assumed to regulate an individual’s attitude toward 
performing a behavior.  
• Normative beliefs are purported the extent to which important people in one’s life 
would approve or disapprove of a behavior being performed. 
• Control beliefs are perceived personal and environmental factors that inhibit 
(barriers) or help (facilitators) the likelihood of performing a behavior. 
• Action control is based on realistic insufficient abilities, skills, and environmental 
constraints that could prevent an individual from acting on intention to perform a 
behavior. 
• Intention is indicative of one’s willingness or readiness to implement a behavior. 
• Behavior is a person’s level of performance to achieve a designated outcome.  
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APPENDIX B 
LETTER OF SUPPORT 
 
Reproductive Resource Center 
Experience. Innovation. Hope. 
April 17, 2018 
Diane Mahoney 
Ph.D. Student 
University of Missouri-Kansas City 
Kansas City, Missouri 64080 
 
Dear Diane:  
 
I am pleased to offer my support for your dissertation study, “Barriers to and Facilitators of 
Infertility Medication Adherence: A Mixed Methods Study.” As the Medical Director of 
Reproductive Resource Center, I believe this research proposal is both timely and important 
in the field of Reproductive Medicine. Determining the patterns and predictors of 
medication non-adherence and implementing strategies to reverse this undesirable behavior 
is very important to maximize the effectiveness of our innovative assistive reproductive 
technology procedures. I provide you access to conduct your study at Reproductive 
Resource Center and I whole heartily offer my support for your compelling work. 
 
 
Sincerely,  
 
 
 
Celeste Brabec, MD  
Fellow of the American College of Obstetrics and Gynecology 
Board Certified, Obstetrics and Gynecology and Reproductive Endocrinology and Infertility 
Medical Director  
Reproductive Resource Center 
12200 West 106th Street, Suite 120 
Overland Park, KS 66215 
913-894-2323 
 
12200 W. 10 6th St., Suite 120 • Overland Park, Kansas 66215 
(913) 894-2323 • fax (913) 894-0841 • rrc.com 
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APPENDIX C 
DEMOGRAPHIC QUESTIONNAIRE 
 
1. Age: _______ Date ___________ 
    
2. Marital Status (“X” ONLY one with which you MOST CLOSELY identify): 
 
  Married 
  Single 
  Divorced 
  Widowed  
      
3. Race (“X” ONLY one with which you MOST CLOSELY identify): 
 American Indian or Alaska Native 
 Asian 
 Black or African-American 
 Hispanic or Mexican American 
 Native Hawaiian or Other Pacific Islander 
 Non-Hispanic White 
 
4. Ethnicity (“X” ONLY one with which you MOST CLOSELY identify): 
 
   Hispanic or Latino 
 Not Hispanic or Latino 
 
5. Which type of community to do you live in? (“X” ONLY one with which you 
MOST CLOSELY identify):  
   Suburban 
 Urban 
 Rural 
 
6. How would you describe you level of infertility insurance coverage? (“X” ONLY 
one with which you MOST CLOSELY identify):  
 
  All self-pay  
  Partial out-of-pocket 
  Full coverage 
 
7. Which category below best describes your household income? (“X” ONLY one with 
which you MOST CLOSELY identify):  
 
   Less than $50,000 
 $50,000 - 74,999 
 $75,000 - $99,999 
 $100,000 - $124,999 
 $125,000 - $ 149,999 
 More than $150,000 
 102 
 
8. Which category below best describes your highest of education? (“X” ONLY one 
with which you MOST CLOSELY identify): 
 
   Less than high school 
 Some high school, no diploma 
 High school graduate, diploma or the equivalent (for example: GED) 
 Some college, no degree 
 Associate degree  
 Bachelor’s degree 
 Master’s degree 
 Doctorate degree 
 
 
9. Please list below the name, dose, and frequency of the infertility medication(s) that 
you are currently taking? 
 
Name of Medication Prescribed Dose How many times per day? 
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APPENDIX E 
ASK-20 ADHERENCE BARRIER SURVEY 
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APPENDIX E 
PERMISSION TO USE ASK-20 ADHERENCE BARRIER SURVEY 
 
April 2, 2018 
Via Email to 
 
Diane Mahoney 
PhD Nursing Student 
University of 
Missouri-Kansas 
City 
descg5@mail.umkc.
edu 
 
RE: Permission to use The Adherence Starts with Knowledge Surveys 
(ASK-12 and ASK-20)  
Dear Ms. Mahoney, 
Thank you for your email of March 20, 2018 requesting permission to use the 
Adherence Starts with Knowledge Survey (ASK-12 and ASK-20) (the “Instrument”) in 
English. We understand you are interested in using the Instrument as part of your 
dissertation research at the University of Missouri-Kansas City to investigate barriers to 
medication adherence among women who are undergoing infertility treatment. 
 
GlaxoSmithKline is pleased to grant you permission to use, reproduce and distribute 
paper and electronic pdf copies of the Instrument in English as part of the above clinical 
study, subject to the following conditions: 
 
1. You may not modify the Instrument or combine it with other instruments without prior 
written approval; 
2. You must use the Instrument in its entirety, with the questions appearing verbatim and 
in order; 
3. You must not remove any trademark ownership statements or copyright notices 
that appear on the Instrument; 
4. You must use the Instrument only for the specific purposes stated in your request; 
5. You must use only the most current version of the Instrument, which, for ease of 
reference, is enclosed with this letter (current as of the date of this letter). 
 
There is no charge for the foregoing permission. You have permission to use the 
Instrument for the specific purposes described in your request. GlaxoSmithKline strictly 
prohibits the reproduction or use of this Instrument for any other purpose without prior 
written consent. We reserve the right to revoke our permission at any time; however, such 
revocation will not affect any use by you of the reproduction in accordance with the 
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permission granted herein prior to such revocation. Please be advised that we cannot make, 
and hereby disclaim, any representations or warranties about this Instrument, including 
any warranties as to additional permissions that may be required for its use. Thank you for 
your interest in GlaxoSmithKline. If you have any questions regarding this matter, please 
contact me at your convenience. 
 
 
Sincerely, 
Matthew S Lau, PharmD, 
MSCR 
Manager, US Value, 
Evidence & Outcomes US 
Medical Affairs 
GlaxoSmithKline 
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APPENDIX F 
INTERVIEW GUIDE 
Facilitators of Medication Adherence 
Opening Statement: There are certain ways people are told to take these medicines. For 
example, take a certain number of pills or injections at a certain time of day. 
 
Describe to me how you are taking your medications? 
 
What helps you take your infertility medicine?  
 
Is there something that anyone else says or does that helps you to continue taking infertility 
medication? If so, please describe. 
 
If you were uncertain about whether you are taking your infertility medicine correctly, what 
would you do? 
 
Personal Experiences with Infertility Treatment 
Transition Statement: Many women choose to receive infertility treatment and each person’s 
experience with infertility treatment is unique. 
 
Think about you—without thinking about anyone else. What impact has receiving infertility 
treatment had on you as a person, I mean your thoughts, feelings, personal characteristics, 
and personal circumstances? 
 
Now, think about people in your life. How has your infertility treatment influenced the 
actions, reactions, and attitudes of these people? 
 
What are your personal concerns about receiving infertility treatment? 
 
Closing Question 
Is there anything else you would like to add about your experience with infertility 
medication or infertility treatment?  
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APPENDIX G 
 
MEDICATION EVENT MONITORING SYSTEM® (MEMS) 
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APPENDIX H 
MEDICATION EVENT MONITORING SYSTEM® (MEMS) DIARY 
 
Subject Number:_____ 
 
Write down any time that you accidentally open the MEMS®, if you don’t get the MEMS® 
cap on tight, if you remove pills before time to take them, or any other situation that you think 
we should know about. This is very important so that we know when your MEMS® may have 
been opened when you didn’t take a pill. This diary will need to be returned to us when you 
return your MEMS® caps. 
 
  
Date Time Explanation of what happened  
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APPENDIX I 
DEFERMENT OF HUMAN SUBJECTS REVIEW TO UMKC IRB 
 
Reproductive Resource Center 
Experience. Innovation. Hope. 
 
August 29, 2018 
 
Dear Diane Mahoney, 
 
To protect the safety and privacy of the patients at Reproductive Resource Center 
while conducting your research study titled, "Barriers to and Facilitators of Infertility 
Medication Adherence: A Mixed Methods Study", I am pleased to defer human 
subjects review to the UMKC Institutional Review Board (IRB). I understand that 
UMKC IRB will thoroughly review your study, grant permission to proceed, and 
provide ongoing oversight of your study. 
 
 Sincerely, 
 
 Celese Brabec, MD 
Fellow of the American College of Obstetrics and Gynecology 
Board Certified, Obstetrics and Gynecology and Reproductive Endocrinology 
and Infertility. Owner and Medical Director 
Reproductive Resource 
Center 12200 West 106th 
Street, Suite 120 Overland 
Park, KS  
913-894-2323 
 
 
 
 
 
 
 
12200 W. 10 6th St., Suite 120 • Overland Park, Kansas 66215 
(913) 894-2323 • fax (913) 894-0841 • rrc.com 
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APPENDIX J 
 
MEDICATION EVENT MONITORING SYSTEM® (MEMS) FOLLOW-UP 
TELEPHONE CALLS 
 
 
Subject Number:_____ 
 
 
 
 
Month #1/ Date_________________ 
 
Do you have any questions about using the MEMS® or MEMS® diary? Tell me 
about how you are using them. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Month#2/ Date__________________ 
 
Do you have any questions about using the MEMS® or MEMS® diary? Tell me 
about how you are using them. 
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